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DEFINITIONS 
Antiretroviral Therapy (ART) 
Refers to when an HIV (Human Immunodeficiency Virus) positive woman takes a 
combination of three antiretroviral drugs both for her own health (treatment) and for 
prevention of mother to child transmission of HIV (prophylaxis). The primary reason for the 
use of triple regimen is for the mother’s health with a secondary reason of preventing mother 
to child transmission of HIV. The triple regimen is started as soon as the mother is assessed 
to be eligible for ART (based on CD4+ cell count and WHO clinical stage) and continued for 
life. 
Antiretroviral Prophylaxis (ARVP) 
Refers to when an HIV-positive pregnant woman takes single, dual or triple antiretroviral 
drugs solely to prevent mother to child transmission of HIV. Triple regimen for ARVP is 
distinct from that of ART in that in the former, the triple regimen is started from 14 weeks of 
gestation and stopped 1 week post cessation of breastfeeding. For the study period (2008 -
2014) women on triple regimen for ARVP have higher CD4
+
 cell count than those on triple 
regimen for ART and were either in WHO Clinical Stage I or II. The terms “Option B” or 
“Triple regimen (ARVP)” were used interchangeably to qualify triple regimen used for 
ARVP throughout this thesis. Triple regimen for ART was referred to as “ART” while 
unqualified triple regimen refers to either “Option B” or “ART”. 
Confirmation of First Test  
Refers to a Deoxyribonucleic Acid (DNA) Polymerase Chain Reaction (PCR) test conducted 
for HIV exposed infants (HEIs) when the attending clinician has reason(s) to doubt the 
outcome of the first DNA PCR test and wants to re-confirm the first result for the 7 years 
under review (2008 – 2014). This is however not officially recognized in the national 
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PMTCT guidelines. It should be noted that DNA PCR test and early infant diagnosis (EID) 
test were used interchangeably throughout the thesis. 
Exclusive Breastfeeding 
Refers to the breastfeeding option where infant is solely fed with breast milk for the first six 
months of life. This option excludes the use of formula feed or any other liquids or solids. 
Use of prescribed medications and oral rehydration salt (ORS) is however allowed.  
First Test for Healthy Exposed Infant 
Refers to the first DNA PCR test conducted for healthy HEI as per the national testing 
algorithm of Nigeria for the 7 years under review (2008 – 2014). 
First Test for Sick Infant 
Refers to the first DNA PCR test conducted for sick HEI as per national testing algorithm i.e. 
the infant has fallen sick at the time of testing for the 7 years under review (2008 – 2014). 
Maternal/Antenatal Human Immunodeficiency Virus (HIV) Positivity Rate 
Refers to the proportion of first ANC attendees that accepted HIV testing that tested HIV 
positive. The numerator for this indicator is the total number of pregnant women that tested 
positive for HIV during the first ANC visit while the denominator is the total number of 
pregnant women that tested for HIV at their first visit. 
Mixed Feeding 
Refers to the breastfeeding option where an infant is fed with both breast milk and formula 
feed or any other liquid or solids. 
MTCT Risk 
Refers to the proportion of tested HEIs that tested HIV positive. The numerator for this 
indicator is the total number of HEIs that tested HIV positive while the denominator is the 
total number of HEIs that tested for HIV. 
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Option B+ 
Refers to the ARV intervention in which an HIV positive pregnant or breastfeeding woman 
takes combination of three antiretroviral drugs for a life time irrespective of CD4
+
 cell count 
and WHO clinical stage. 
Period 1 (Jan 2008 – Jan 2010) 
Refers to the period when only the 2007 National PMTCT guidelines was in use for PMTCT 
at the two health facilities used for this study. 
Period 2 (Jun 2012-Dec 2014) 
Refers to the period when only the 2010 National PMTCT guidelines was in use for PMTCT 
at the two health facilities used for this study. 
Problem with First Test  
Refers to the repeat DNA PCR test conducted when the first dried blood spot (DBS) sample 
collected was either not testable or the result did not get to the ordering health facility hence 
the need to reorder the "first" test for the 7 years under review (2008 – 2014). For a test to be 
in this category the result of the first test ordered must have been indeterminate or missing. 
Repeat Test 6 weeks Post Cessation of Breastfeeding  
Refers to the second (and final) DNA PCR test conducted for HEI at six weeks post cessation 
of breastfeeding as per Nigeria’s national testing algorithm for the 7 years under review (2008 
– 2014). 
Replacement Feeding /Not Breastfed at all 
Refers to the breastfeeding option where an infant is never fed with breast milk. The infant is 
fed with formula feed or any liquid or solid meal. 
Secondary Health Facility 
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Refers to health facilities that provide secondary health care; these health facilities provide 
specialized services to patients referred from the primary health care level (first point of 
medical consultation) and are managed by the state governments. 
Tertiary Health Facility 
Refers to health facilities that provide highly specialized referral services to the primary and 
secondary levels of the health care delivery system and are largely managed by the federal 
government. Most of the tertiary health facilities also serve as teaching hospitals for medical 
training.   
Transitional Period (Feb 2010 – May 2012) 
Refers to the period when both the 2007 and 2010 National PMTCT guidelines were in use 
for PMTCT at the 2 health facilities used for this study. 
Turnaround Time 
Refers to the time interval (in days) between when a DBS sample was collected from HEI 
and when the DNA PCR result was returned to the ordering health facility.  
Uptake of ART/ARVP  
Refers to the proportion of ANC attendees who tested HIV positive at their first visit that 
received antiretroviral drugs (ARVs) (either for prophylaxis or treatment). The numerator for 
this indicator is the total number of pregnant women that received ARVs (either for 
prophylaxis or treatment) while the denominator is the total number of pregnant women that 
tested positive for HIV at the first ANC visit. 
Uptake of HIV Testing and Counselling (HTC)  
Refers to the proportion of pregnant women that attended ANC for the first time in the most 
recent pregnancy that tested for HIV. The numerator for this indicator is the total number of 
pregnant women that tested for HIV during their first visit while the denominator is the total 
http://etd.uwc.ac.za
xv 
 
number of pregnant women that attended ANC for the first time in the most recent 
pregnancy.  
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ABSTRACT 
Background: Most (90%) Human Immunodeficiency Virus (HIV) positive children are 
infected through mother to child transmission of HIV (MTCT). Without any interventions the 
risk of MTCT is between 20% and 45% at the final endpoint of 18 – 24 months. Efficacy 
studies have however proven that with antiretroviral interventions, MTCT risk can be 
reduced to less than 2% or 5% in non-breastfeeding and breastfeeding populations 
respectively. It is important to evaluate the effectiveness of Prevention of MTCT (PMTCT) 
interventions in routine health facility settings where service delivery may not be optimal. 
The current pool of evidence on PMTCT effectiveness in Sub-Saharan Africa is limited and 
no PMTCT effectiveness study has been conducted in Adamawa State, Nigeria since the 
programme started in 2007. 
Aim:  To evaluate the effectiveness of the PMTCT programme in two health facilities in 
Adamawa State, Nigeria. 
Methodology:  This study involved a retrospective review and analysis of routine antenatal 
clinic (ANC), PMTCT/HIV Testing and Counseling (HTC) and early infant diagnosis /infant 
follow up records gathered from 2008-2014 (seven years) in two health facilities in Adamawa 
State, Nigeria. Routine data were analyzed using STATA 14.2 to establish uptake of HTC 
among ANC attendees, uptake of antiretroviral therapy (ART)/antiretroviral prophylaxis 
(ARVP) among those that tested HIV positive, turnaround time (TAT) for Deoxyribonucleic 
Acid (DNA) Polymerase Chain Reaction (PCR) test results and MTCT risk among HIV 
exposed infants (HEIs) segregated by age, breastfeeding option, ART/ARVP option and 
PMTCT protocol periods. Simple and multiple logistic regression analyses were conducted to 
establish predictors of ART/ARVP uptake and MTCT risk. 
Results: Among the 62,224 pregnant women (FMC Yola = 14,892; SH Yola = 47,332) that 
attended ANC for the first time from 2008 to 2014, the overall uptake of HTC was estimated 
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xvii 
 
to be 75.9% [47,217/62,224] (95% Confidence Interval: 74.3% – 77.5%). This increased 
from 60.8% [5,365/8,824] (49.9%-71.7%) in 2008 to 82.2% [7,636/9,293] (77.1%-87.2%) in 
2014. Average maternal HIV positivity rate among the 47,217 pregnant women tested for 
HIV was 3.1% [1,475/47,217] (3.0% - 3.3%) across the seven years, ranging from 5.5% 
[297/5,365] (4.8% - 6.2%) in 2008 to 1.5% [117/7,636] (1.2% - 1.9%) in 2014. The overall 
uptake of ART/ARVP among 224 HIV positive pregnant women was 85.7% [192/224] 
(81.1% - 90.3%), increasing from 76.5% [13/17] (55.6%-97.4%) in 2008 to 80.0% [52/65] 
(70.1%-89.9%) in 2014. The overall MTCT risk among 1,651 HEIs (FMC Yola = 746, SH 
Yola = 905) with first DNA PCR test results across the seven years was 9.7% [160/1,651] 
(8.3%-11.1%) at median age of 8 weeks (IQR: 6-20), decreasing from 14.3% [7/49] (4.4%-
24.2%) in 2008 to 4.9% [11/226] (2.1%-7.7%) in 2014. Across all seven years, pooled data 
demonstrated that infants aged ≤ 6 weeks and those between >6 months and 12 months had a 
cumulative MTCT risk of 3.0% [15/499] (1.5% - 4.5%) and 21.1% [51/242] (15.9%-26.2%) 
respectively; infants that were exclusively breastfed, mixed fed and those not breastfed at all 
had MTCT risks of 8.3% [74/892] (6.5% - 10.1%), 22.4% [58/259] (17.3% - 27.5%) and 
5.4% [23/429] (3.2% - 7.5%) respectively at median age of 8 weeks; MTCT risk was 2.4% 
[25/1,034] (1.5% – 3.4%) when both mother and infant received antiretroviral drugs 
(ART/ARVP) and 48.8% [83/170] (41.3% - 56.4%) when they did not at median age of 8 
weeks. MTCT risk was lowest (5.4% [39/726] (3.7% - 7.0%)) during the period (June 2012 – 
December 2014) when Option B was in use for ARVP at median age of 8 weeks. The overall 
median TAT for DNA PCR test results was 48 days (IQR: 31-78) (n=1,298), increasing from 
37 days (31-51) (n=49) in 2008 to 133 days (76-172) (n=168) in 2014. Multiple regression 
analysis showed that HIV positive pregnant women aged between 25-34 years had three 
times (Adjusted Odds Ratio (AOR) 3.07 [1.04 - 9.01]) the odds to receive ART/ARVP than 
those aged 15-24 years. The odds of being HIV positive was higher in HEIs that were older 
http://etd.uwc.ac.za
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than 12 months (AOR 3.29 [1.24 - 8.75]), those that were mixed fed (AOR 2.44 [1.08 - 5.52]) 
and when neither mother nor HEI received ART/ARVP (AOR 26.37 [13.96 - 49.81]. HEIs 
born in 2012 had lower odds (AOR 0.18 [0.03 – 0.99]) of being HIV positive than those born 
in 2008.  
Conclusion: Despite operational challenges, MTCT risk declined drastically between 2008 
and 2014 in these two routine health facility settings in Nigeria and this reduction in MTCT 
coincided with an increase in the uptake of HTC services and ART/ARVP among HIV 
positive pregnant women. Option B or Option B+ is therefore strongly recommended, where 
feasible, to achieve elimination of MTCT as a public health problem.  
http://etd.uwc.ac.za
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1.0 INTRODUCTION 
 
1.1 Background 
Human Immunodeficiency Virus (HIV) infections disproportionately affect women and 
children with approximately 37,000 pregnant women dying of the virus globally in 2010 
(WHO, 2015a; WHO, 2015b; WHO, 2015c; UNAIDS, 2012). Most (over 90%) HIV-positive 
children (aged 0-14 years) were infected through mother to child transmission of HIV 
(MTCT) (WHO, 2010d; WHO, 2015e). Without any interventions, the risk of MTCT is 
between 20-45%, while with antiretroviral interventions the risk of MTCT can be reduced to 
less than 2% and 5% in non-breastfeeding and breastfeeding populations, respectively, at the 
final endpoint of 18 – 24 months (De Cock et al., 2000; Kumar, Uduman, & Khurranna, 
1995; Lallemant et al., 1994; WHO, 2010a). MTCT can occur during pregnancy, childbirth 
(labour and delivery) and breastfeeding (WHO, 2010a).  Research has demonstrated that most 
cases of MTCT occur late in pregnancy and during delivery due to contact between the 
maternal and fetal blood when the placenta separates from the uterine wall and as the infant 
passes through the birth canal (for babies delivered through the vaginal route) (Kourtis et al., 
2001; Rouzioux et al., 1995). When infants are breastfed, the postnatal period is also critical 
as around 39% of cumulative MTCT can occur during this period (Kourtis et al., 2006). 
Factors such as viral load (VL), mode of delivery and feeding practice (breastfeeding versus 
avoiding breastfeeding, exclusive breastfeeding versus mixed breastfeeding) have been found 
to influence the risk of MTCT (Newell, 2001). HIV-infected women with high VL are more 
likely to infect their children while elective cesarean section reduced MTCT risk by half in 
some settings (Newell, 2001). Research has also demonstrated that mixed-fed infants have 
higher MTCT risk than exclusively breastfed or formula fed infants while the risk of MTCT 
http://etd.uwc.ac.za
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increases with the duration of breastfeeding (Newell, 2001; Wise, 2001; The Breastfeeding 
and HIV International Transmission Study Group et al., 2004).  
 
Interventions geared to prevent MTCT follow a cascade of steps which begins with HIV 
testing and counseling (HTC) of the pregnant mother and culminates in establishing the HIV 
status of the HIV-exposed infant (HEI) and enrolment of the HIV-positive child into HIV 
care and treatment as presented in Appendix 1 (see Appendix 2 for Nigeria’s eligibility 
criteria and recommended antiretroviral drugs (ARVs) between 2007 and 2014 (Federal 
Ministry of Health, 2007; Federal Ministry of Health Nigeria, 2010a; Federal Ministry of 
Health, 2014a)). It is important to evaluate the effectiveness of these interventions to 
determine real-life impact of interventions to prevent MTCT. Currently, the numbers of 
Prevention of Mother to Child Transmission of HIV (PMTCT) effectiveness studies are 
limited in Africa ((Goga, Dinh, & Jackson, 2012; Lussiana et al., 2012; Nkwo, 2012; Goga et 
al., 2016).   
1.2 Problem statement 
As asserted by UNAIDS in 2011, it is possible to keep pregnant HIV-positive women alive 
and prevent new infant HIV infections by timely provision of appropriate ARVs either as 
treatment for the mother’s health or as ‘treatment as prophylaxis’ to prevent MTCT 
(UNAIDS, 2011). Even though efficacy of PMTCT is established, there are real life scenarios 
that are not accounted for by the controlled conditions under which efficacy studies are 
conducted. Adamawa State, Nigeria commenced implementation of the PMTCT programme 
in September, 2007; however no study has been carried out to investigate the effectiveness of 
the interventions provided.  
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1.3 Purpose 
The World Health Organization (WHO) has recommended that all countries track the 
achievement of elimination of MTCT (eMTCT) targets even beyond 2015 (WHO, 2011; 
WHO, 2014). To date, the only country-level findings available in Nigeria are from 
operational research conducted in 2005 when only 11 tertiary sites offered PMTCT services 
(Agboghoroma, Sagay, & Ikechebelu, 2013). 
The purpose of this research project was therefore to evaluate the effectiveness of the 
PMTCT interventions provided in two health facilities in Adamawa State, Nigeria. This 
would help in several ways: (i) service providers would get to know the effectiveness of 
PMTCT-related interventions/investments; (ii) it would help the Strengthening Integrated 
Delivery of HIV/AIDS Services (SIDHAS) programme meet one of its programme objectives 
of providing evidence on the effectiveness of PMTCT interventions in two of their supported 
health facilities; (iii) it would also add to the body of knowledge and provide evidence on the 
effectiveness of the programme in two large health facilities after over a decade of PMTCT 
implementation in Nigeria; (iv) while most of the facility-based PMTCT effectiveness studies 
in Nigeria were single-site studies conducted at tertiary or teaching hospitals (Agboghoroma, 
Audu and Iregbu, 2015; Chama, Gashau, & Oguche, 2007; Chama et al., 2010; Esene & 
Omoigberale, 2012; Okafor et al., 2014; Isah et al, 2016), this study included a secondary 
health facility , thus providing additional evidence on PMTCT effectiveness in a secondary 
health facility which may not have as much specialized health personnel as tertiary or 
teaching hospitals; (v) most published Nigerian studies report findings during one period of 
the PMTCT protocol (Agboghoroma, Audu and Iregbu, 2015; Chama, Gashau, & Oguche, 
2007; Afe et al., 2011; Audu et al.,2014; Anoje et al., 2012; Sagay et al., 2015; Kalu et al., 
2014; Chukwuemeka et al., 2014); this study however compared MTCT risks during 2 
periods of PMTCT policy changes in Nigeria as well as during the transitional period and (vi) 
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the sample sizes used in this study were also larger than most of the other Nigerian studies 
(see appendix 5). 
1.4  Aim 
This study aimed to evaluate the effectiveness of the PMTCT programme in two health 
facilities in Adamawa State, Nigeria.  
1.5 Objectives 
The objectives of this study were to: 
1. determine the uptake of HTC by pregnant women attending ANC for the first time in 
the most recent pregnancy 
2. describe maternal/antenatal HIV positivity rate between 2008 and 2014 
3. determine the uptake of maternal antiretroviral therapy (ART)/antiretroviral 
prophylaxis (ARVP) amongst HIV positive pregnant women 
4. determine overall MTCT risk and turnaround time for DNA PCR test results 
5. determine the MTCT risk at ages 4 weeks to 2 months, >2months – 6 months,  >6 
months to 12 months and >12 months 
6. compare the MTCT risk by receipt/non-receipt of antiretroviral drugs (prophylaxis 
versus treatment) amongst HIV positive mothers  
7. compare the MTCT risk by breastfeeding option (exclusively breast fed, mixed fed 
and not breastfed at all) 
8. compare MTCT risk during two periods of PMTCT protocol policy changes and the 
transitional period (Period 1 - Jan 2008 – Jan 2010, Transitional Phase - Feb 2010 – 
May 2012 and Period 2 - Jun 2012-Dec 2014) 
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2.0 LITERATURE REVIEW 
This chapter provides a brief overview of the burden of HIV/AIDS across the globe and in 
Nigeria. It then summarizes the evolution of the PMTCT programme in Nigeria, the PMTCT 
cascade and the PMTCT regimens that were in use in Nigeria from 2007 to 2014. Finally this 
chapter concludes with a review of the recommended methodologies for evaluating 
effectiveness of PMTCT and some findings from previous national and facility-level PMTCT 
effectiveness studies in other countries and Nigeria.  
2.1 The global burden of HIV and AIDS 
The burden of HIV and AIDS is of major public health concern both in Africa and the world 
at large (Ortblad, Lozano, & Murray, 2013). According to WHO, as at end of 2013, the 
global population of people living with HIV/AIDS (PLHIV) stood at 35 million (WHO, 
2015d). Since the start of the HIV/AIDS epidemic, approximately 39 million lives have been 
claimed by the virus (WHO, 2015d). Sub Saharan Africa bears the highest burden of 
HIV/AIDS (WHO, 2015d) as 71% of PLHIV are resident in the region (WHO, 2010a; WHO, 
2015d) even though it is home to approximately one-eighth of the world’s population (The 
World Bank Group, 2017).   
Approximately 55% of all people infected with HIV/AIDS are women and children (WHO, 
2015a; WHO, 2015b; WHO, 2015c). In 2010, HIV infection was responsible for 
approximately 37,000 deaths among pregnant women globally (UNAIDS, 2012). In 2015, an 
estimated total of 150,000 children were newly infected with HIV in low- and middle-income 
countries (UNAIDS, 2016a); most (over 90%) of these children (aged 0-14 years) were 
infected through MTCT (WHO, 2010a). Given the higher risk of MTCT associated with 
breastfeeding and vaginal delivery, many developed countries have adopted combination of 
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ARVP, elective caesarian section and replacement feeding as set of interventions for PMTCT 
(Darak et al., 2014).  
2.2 Uptake of HTC and ART/ARVP 
To establish the HIV status of pregnant women during ANC, the attendee must accept to test 
for HIV. The major approaches employed for this are the “opt in” and “opt out” methods 
(Walmsley, 2003). In the former, pregnant women are informed about the availability of 
screening service and are given the liberty to request for the test if they so wish. In the latter 
approach however, screening for HIV is offered as part of routine ANC services and the only 
pregnant women that are not screened are those that do not give their consent. This latter 
approach has been the recommended method for HIV screening among ANC attendees in 
Nigeria since 2007 (Federal Ministry of Health, 2007; Federal Ministry of Health Nigeria, 
2010a; Federal Ministry of Health, 2014a). This testing strategy did not change in Nigeria 
between 2008 and 2014 and women that test positive for HIV are placed on antiretroviral 
drugs. 
Available evidence shows that the “opt out” approach is associated with a higher level of 
uptake when compared to the “opt in” method (Walmsley, 2003). 
 
Reported data across selected 13 African countries in 2010 suggested that HTC uptake can 
range between  nine percent as seen in Democratic Republic of Congo (DRC) to as high as 
>95% in South Africa and Zambia. Uptake of ARV among HIV positive women was also the 
lowest in DRC (4 -11%) while the highest rate of >95% was among Botswana women 
(Adane, 2012). 
According to NDHS 2013 only 20 percent of women surveyed in Nigeria were counselled, 
tested and received result during ANC. The rate of ~39% for Adamawa State is above this 
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national average. UNAIDS (2016b) noted that only 30% of pregnant women living with HIV 
in Nigeria are accessing ARVs to prevent MTCT. 
A number of factors can affect uptake of HTC/ARVP as well as other elements of PMCT 
interventions. Based on the study reported by Chabikuli et al. (2013), poor quality counseling 
by the healthcare worker due to high workload was one of the factors constraining service 
delivery. Counselling has wide ranging effect on the client’s decision to accept HIV testing 
and adhere to treatment. Mirkuzie et al. (2011) in their study in Addis Ababa observed a 
decline in medication adherence across the perinatal period. It is often assumed that once 
HIV positive mothers receive prophylaxis, they end up using the medication. This study 
however revealed decline in adherence which might be as a result of poor counseling. NACA 
(2013) also acknowledged poor counseling on infant feeding as one of the problems plaguing 
PMTCT programme in Nigeria. While work overload might be one of the reasons why 
counseling is poor; a study conducted in one of the states in Nigeria suggested that 
knowledge gap could also be responsible (Ndikom & Onibokun, 2007; Nkwo, 2012). The 
study reported that nurses were moderately knowledgeable about PMTCT with fairly 
appropriate behavior and recommended the need for educational interventions and a more 
conducive environment for practice (Ndikom & Onibokun, 2007). 
Staff attrition was also reported by Chabikuli et al. (2013) while a rapid assessment in the 
Eastern Cape province of South Africa equally identified lack of staff and inadequate training 
as factors plaguing PMTCT service delivery (Peltzer et al., 2008). 
Inadequate resources for service delivery including shortage of ARVs required for 
prophylaxis also impact negatively on service delivery in a wide variety of settings (NACA, 
2013; Oladokun et al., 2010; Chama, Audu & Kyari, 2004). Follow up of HIV pregnant 
women and HIV exposed infants is equally crucial. Inadequate follow up was identified in a 
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study carried out in Uganda using key informants working in five PMTCT sites in the 
country (Nuwagaba-Biribonwoha et al., 2007); the study by  Chabikuli et al. (2013) also 
identified inadequate resources for patient tracking as a challenge. 
In Uganda, reluctance to test, non-disclosure of HIV status and difficulties with infant 
feeding for HIV positive patients were identified as barriers to PMTCT service provision. A 
variety of studies have also identified lack of  male partner involvement in testing, stigma and 
discrimination as well as illiteracy (Rogers-Bloc & Quail, 2002; Peltzer et al., 2008; 
Oladokun et al, 2010) as constraining factors. Instances also exist where patients do not 
return for prophylaxis after test due to lack of finance, domestic violence amongst other 
reasons (Chabikuli et al., 2013).  
2.3 Diagnosis of infant HIV infection 
Given that maternal antibodies are retained in infants’ foetal circulation for up to eighteen 
months after birth, tests that rely on detection of HIV antibodies are not used for the 
diagnosis of HIV infection in children (WHO, 2010b). HIV infection is diagnosed in infants 
using PCR test. Unlike antibody test, the PCR test detects viral antigens in the blood of HEIs. 
The blood sample is typically collected from the heel of the HEI using a dried blood spot 
(DBS) and then transported to a central laboratory where the sample is analyzed with the 
final result shared with the originating health facility. The use of DBS eases collection of 
blood samples at a relatively cheap rate and do not require high level of expertise (Smit, 
2014). Collected samples can be stored over an extended period of time and are also easily 
transported to the central laboratory (Smit, 2014). As of 2012, there were 23 PCR 
laboratories across the states in Nigeria (CHAI, 2012). Early diagnosis of HIV in infants is 
critical as this ensures that HIV positive infants are promptly initiated on ART with 
consequent increase in chances of child survival (WHO, 2010b). 
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2.4 Turnaround time for PCR test results 
Findings from nine studies carried out in six African countries (Botswana, Kenya, Côte 
d'Ivoire, Swaziland, Tanzania, and South Africa) between 2008 and 2011 as reported by 
Ciaranello et al. (2011) revealed that turnaround time (TAT) can range between four and 147 
days. The lowest median estimate of nine days was for the study conducted in Botswana 
while the highest TAT of 70 days (for negative PCR results) was reported for one of the 
studies conducted in Tanzania. Another study conducted in a rural clinic in Southern Zambia 
reported a median TAT of 54 days (IQR: 38-73; n = 462) while the study carried out at a 
regional referral hospital in Uganda between January 2008 and February 2009 reported a 
lower median TAT of 38 days (IQR: 25-54) (Sutcliffe et al., 2014; Mugambi et al., 2013)  
A nationally representative study conducted in Zimbabwe from August to December 2012 
showed that more than 80 percent of facilities had TAT that were more than four weeks 
(Wiegert et al., 2014). 
Studies had also shown that various interventions can reduce TAT. Following centralization 
of DNA PCR testing through the use of hub network system, TAT reduced from 49 days 
(greater than 55 in rural areas) to 26 days in Uganda while introduction of SMS printers 
resulted in a further decrease to 14 days (Kiyaga et al., 2013). HIV Infant Tracking System 
(HITSystem) that sends automatic text message alerts to service providers, laboratory 
technicians and mothers in order to trigger action also reduced TAT in Kenya (Urban: 6.3 
(4.7–13·6) for control group Vs  5.0 (3.7–6.1) for intervention group p<0.001 and Peri-
Urban: 8.1 (4.9–12.9) for control  group Vs  3.4 (2.8–4.7) for intervention group p<0.001; all 
in weeks) (Finocchario-Kessler et al., 2014). 
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The study conducted by Anoje et al. (2012) at six health facilities in two states in South-
South Nigeria estimated the median TAT to be 47 days (IQR: 35-58) (57 days for rural 
settings versus 40 days for urban locations; p<0.01). A lower median TAT of 25 days was 
reported by Audu et al. (2014) for the study they conducted in six health facilities in Lagos 
State, Nigeria. In general TAT is typically higher for rural locations than for urban areas 
(Anoje et al., 2012; Kiyaga et al., 2013). This is likely due to the longer distance that needs to 
be covered for sample transportation and result transmission. 
2.5 HIV/AIDS and PMTCT in Nigeria 
Nigeria has the highest number of children living with HIV in the world (about 260 000 (190 
000 - 360 000)) in 2015 (UNAIDS, 2016a; UNAIDS 2017). An estimated 41 000 (28 000–57 
000) children in the country were newly infected with HIV in 2015, representing 27% of the 
global new pediatric HIV infections for the year (UNAIDS, 2016a). Approximately 2.2 
million children in Nigeria have been orphaned by HIV/AIDS (Federal Ministry of Health 
Nigeria, 2010a).  
In order to prevent MTCT, Nigeria implemented the PMTCT programme in 2002 in six 
health facilities; one in each geo-political zone of the country (Agboghoroma et al., 2013). 
This was subsequently scaled up to 11 tertiary health facilities with 10 of these health 
facilities in operation by 2003 (Agboghoroma et al., 2013; Federal Ministry of Health 
Nigeria, 2010a). By the end of December 2012, a total of 1,320 health facilities comprising 
tertiary, secondary, primary and private health facilities were offering PMTCT services in 
Nigeria (National Agency for the Control of AIDS, 2014). These programmes are largely 
supported through international donor agencies (Agboghoroma et al., 2013) with the United 
States Government President’s Emergency Plan for AIDS Relief (PEPFAR) ranking as the 
largest funder (supports 75% of the country’s HIV programme) of HIV programme in the 
country (Ezegbe & Stephenson, 2012). 
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As recommended by WHO, Nigeria implements a comprehensive 4-pronged strategy to 
prevent HIV/AIDS in infants and children (Ezegbe & Stephenson, 2012; Federal Ministry of 
Health Nigeria, 2010a). The strategy includes: primary prevention of HIV infection in women 
of reproductive age and their partners; prevention of unintended pregnancies among HIV 
positive women; prevention of HIV transmission from HIV infected mothers to their infants 
and care and support for HIV infected mothers, their infants and family members (Federal 
Ministry of Health Nigeria, 2010a). The first PMTCT guidelines in Nigeria was produced in 
2001 and was reviewed in 2005, 2007, 2010, 2014 and 2016 (Agboghoroma et al., 2013; 
Federal Ministry of Health, 2016)- the 2007 and 2010 PMTCT guidelines were the guidelines 
in use during the study period. The PMTCT strategy aligns with Nigeria’s National PMTCT 
scale up plan (2010-2015) which has the overarching goal of improving maternal health and 
child survival through the provision of comprehensive PMTCT services, see targets in 
Appendix 3 (Federal Ministry of Health Nigeria, 2010a). 
2.5.1 PMTCT cascade in Nigeria 
As shown in Appendix 1, the PMTCT cascade in Nigeria starts with the offering to and 
acceptance of HIV testing and counselling by pregnant women that attend ANC. Pregnant 
women that test positive for HIV are evaluated for ART eligibility while women test negative 
are re-tested in three months’ time. ART-eligible pregnant women are placed on ART while 
ineligible women receive ARVP. Details of eligibility criteria and ARVs used between 2007 
and 2014 are available in sections 2.5.2-2.5.4 and Appendix 2. 
In addition, HIV positive women are counselled on infant feeding options. The first option is 
for mothers to breastfeed exclusively for the first six months after which complementary 
feeds can be introduced and feeding continues for up to 1 year. The second option is for 
mothers to avoid breastfeeding, using replacement milk (commercial infant formula and 
others). However as this is associated with an increased risk of child morbidity and mortality, 
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replacement feeding is only recommended between 2008 and 2014 if the AFASS 
(Acceptable, Feasible, Affordable, Sustainable and Safe) criteria are met. Currently in 
Nigeria, women are strongly advised to adopt the first option.  
HIV positive pregnant women are typically advised to deliver at the health facility. Upon 
delivery, HEIs receive ARV prophylaxis and are tested for HIV at six weeks of birth and six 
weeks post cessation of breastfeeding using DNA PCR. ART is immediately commenced if 
any of these two tests turn out to be positive (Federal Ministry of Health, 2007; Federal 
Ministry of Health Nigeria, 2010a; Federal Ministry of Health, 2014a).  
2.5.2 ART and PMTCT eligibility criteria: Nigeria’s 2007 PMTCT guidelines 
The 2007 guidelines recommended that a woman is eligible for ART if she is in WHO 
Clinical Stage IV irrespective of CD4+ cell count, WHO Clinical Stage III if her CD4+ cell 
count is < 350 cells/mm
3
 and if her CD4+ cell count is ≤ 200 cells/mm3 irrespective of WHO 
clinical staging. Women that did not meet ART eligibility criteria were placed on ARVP 
(Federal Ministry of Health, 2007). 
2.5.3 ART and PMTCT eligibility criteria: Nigeria’s 2010 and 2014 PMTCT 
guidelines 
The 2010 and 2014 guidelines stipulated that a woman is eligible for ART if she is in WHO 
clinical stages III or IV irrespective of CD4+ cell count. While the 2010 guideline stipulated a 
CD4+ cell count of ≤350 cells/mm3 irrespective of WHO clinical stage the 2014 guidelines 
stipulated a CD4 cell count of ≤500 cells/mm3 irrespective of WHO clinical stage for ART 
eligibility. ART ineligible women were placed on ARVP (Federal Ministry of Health Nigeria, 
2010a; Federal Ministry of Health, 2014a).  
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2.5.4 PMTCT regimens used in Nigeria 
Single dose Nevirapine (sdNVP)/Nevirapine (NVP) (2007 to date)  
Though not currently in use as monotherapy for PMTCT due to availability of more effective  
ARV combination and concerns around resistance, Nigeria’s 2007 PMTCT guideline 
recommended sdNVP at the onset of labour for mothers as part of their PMTCT regimen and 
also at birth for HEIs. Similarly the 2010’s guideline recommended sdNVP at onset of labour 
and delivery as part of PMTCT regimen (Option A). From 2010 upwards, daily dose of NVP 
is recommended for HEIs for 6 weeks or more (see appendix 2) in Nigeria. Effectiveness 
studies have shown that sdNVP as monotherapy is the least effective for preventing MTCT 
which justifies why it is no longer used for maternal ARVP (Chama, Gashau, & Oguche, 
2007; Moodley et al., 2013). 
Zidovudine plus sdNVP (2007 – 2014)  
Nigeria’s 2007 and 2010 PMTCT guidelines recommended Zidovudine (AZT) from 28 and 
14 weeks (Option A) respectively for PMTCT in addition to sdNVP at the onset of labour and 
delivery. This regimen is followed by AZT+3TC during labour and delivery and continued 
for 1 week post-partum. Up until 2014, AZT (Option A) was the major ARV used for 
maternal ARVP in health facilities that only provide PMTCT services (and not 
comprehensive ART services) in Nigeria. The 2007 guideline equally recommended AZT for 
6 weeks for HEIs. AZT has been acclaimed to be the oldest and the most studied of all ARVs 
used for PMTCT (Connor et al., 1994; Paintsil & Andiman, 2009; Thorne & Newell, 2007). 
Zidovudine plus Lamivudine (2007 – 2014) 
In Nigeria, this dual combination was used for maternal ARVP (at the onset of labour/during 
labour and delivery as well as post-partum) between 2007 and 2014. It is also worthy to note 
that between 2007 and 2010, pregnant women diagnosed with HIV at 34-36 weeks of 
gestation received AZT+3TC instead of just AZT.  
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Triple regimen (2010 till to date) 
Following the release of ART treatment guidelines by WHO in 2010, Nigeria in 2010 
adopted the use of triple regimen (Option B) for PMTCT in health facilities (mainly 
secondary and tertiary) that can monitor pregnant women placed on this regimen. Some of 
the recommended triple regimens are: 
o AZT + 3TC + EFV  
o AZT + 3TC + NVP   
o AZT + 3TC + LPV/r 
o TDF+ 3TC+ EFV 
While in 2010, the triple regimen is recommend from 14 weeks of gestation, by the end of 
2014 HIV positive pregnant women in all health facilities in the country are expected to be 
placed on triple regimen irrespective of gestation age and CD4+ cell count and continued till 
one week post cessation of breastfeeding. Studies have established the triple regimen as the 
most effective PMTCT regimen (Adane, 2012).   
 
2.6 Evaluation of PMTCT programmes  
2.6.1 PMTCT programme evaluation: Global  
 
The WHO’s technical consultation report titled “Towards the elimination of Mother-to-Child 
Transmission of HIV: Report of a WHO technical consultation  9-11 November 2010 
Geneva, Switzerland” noted the need to track progress towards meeting the  PMTCT targets 
to eliminate overall MTCT to less than 5% by the end of 2015  (WHO, 2011). Few studies 
have however been conducted to evaluate the effectiveness of these interventions in resource 
limited settings and in particular Nigeria (Lussiana et al., 2012; Nkwo, 2012). Evaluation of 
effectiveness is important even though the efficacy of PMTCT has been established in a 
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number of carefully designed and well controlled clinical trials such as PACTG076/ANRS 
024 trial, DITRAME/Plus ANRS 1201.1 trial and Thai ZDV + 3TC trial (see appendix 4) 
(Chaisilwattana et al., 2002; Connor et al., 1994; Dabis et al., 2005). These efficacy studies 
do not take into account the uncertainties around service provision in programmatic settings 
hence the need to evaluate effectiveness at operational level (Chabikuli et al., 2013; Stringer 
et al., 2008). Effectiveness of PMTCT is an impact evaluation and it is defined as the 
“prophylactic benefit of a PMTCT intervention when implemented in real practice” (Stringer 
et al., 2008). There is no standard measure of PMTCT effectiveness as studies often report 
one of the following indicators: PMTCT intervention coverage (used as proxy for infant 
infections prevented); actual infant infections prevented; infant deaths prevented and HIV-
free survival (Stringer et al., 2008). According to Stringer et al. (2008) any component of 
PMTCT cascade can also be used to evaluate the effectiveness of PMTCT programme 
(Stringer et al., 2008; UNICEF, WHO, & UNAIDS, 2009). This however could be debatable. 
Assessing the HIV status of an HEI at 6 weeks post-delivery and 6 weeks after cessation of 
breastfeeding provides a way of estimating the number of infant infections prevented (WHO, 
2012).  
Studies have evaluated PMTCT programme effectiveness at a national scale. In Canada, 
effectiveness was evaluated by reviewing routine PMTCT data reported from 22 HIV referral 
sites between 1990 and 2010 through the National Perinatal HIV Surveillance Programme 
(Forbes et al., 2012). The evaluation (which only included HIV positive women that were 
referred before, during or within 3 months of delivery, n=2,692) yielded an overall MTCT 
risk (1990-2010) of 5.2%, dropping from 20.2% (1990-1996) to 2.9% (1997-2010). MTCT 
risk for pregnant women on ART was 1.0%; in women receiving more than 4 weeks of ART, 
the risk of MTCT was 0.4% compared with 9.0% in women receiving less than 4 weeks of 
ART. In mothers exposed to ARVP (2 drugs) or no ART, HEIs born through caesarian 
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section had a lower risk of MTCT than those born through vaginal delivery (3.8% compared 
with 10.3%; p=0.016). Race, which is often a proxy for socio economic status and access to 
services, was also a risk factor as Blacks and Aboriginals were found to form the highest 
proportion of HIV positive pregnant women (Forbes et al., 2012). South Africa and some 
other African countries like Kenya, Mozambique, and Rwanda had also conducted national 
evaluations of their PMTCT programme in order to track progress (IAS, 2011). Given that 
South Africa has high immunization coverage of over 99%; their evaluation was based on 
collecting DBS samples of infants attending immunization clinic for HIV PCR testing. The 
evaluation revealed high uptake (of over 90%) for both HTC during pregnancy and ARVP 
and a population-level perinatal MTCT risk of 3.5% in 2010 for infants aged 4-8 weeks. 
MTCT at 18 months will be a better measure of postnatal PMTCT effectiveness, but these 
population-level data are sparse. This was rightly acknowledged by the report (Goga, Dinh, & 
Jackson, 2012; Leach-Lemens, 2011). Results from another evaluation that assessed HIV free 
survival by 18 months in South Africa was released in 2016 (Goga et al., 2016). The 
nationally representative survey estimated the infant HIV exposure at 4-8 weeks (n=9,120) to 
be 33.1% (31.8% - 34.3%) in 2012-13 while MTCT risk was 2.6% (2.0%-3.2%). Among 
1,880 (71%) of HEIs that were followed up for 18 months, cumulative MTCT risk and 
''MTCT risk-or-death'' by 3, 6, 12 and 18 months were 2.7% (2.6%-12.6%) and 2.8% (2.6%-
19.0%); 3.5% (3.1%-4.4%) and 4.2% (3.5%-5.4%); 3.9% (3.4%-4.7%) and 5.7% (5.0%-
6.8%); 4.3% (3.7%-5.0%) and 6.2% (5.5%-7.3%) respectively. Eighty one percent of the 
MTCT and 67% of ''MTCT-or-death'' occurred by 6 months postpartum (Goga et al., 2016). 
Evidence from several smaller scale studies that assessed PMTCT effectiveness is 
summarized in appendix 5. In the KwaZulu-Natal province of South Africa, studies have 
reported a MTCT risk at 6 weeks that ranges from 27.5% (95% Confidence Interval (CI): 
19.1 – 36.2%) when the PMTCT drug regimen only included single dose Nevirapine 
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(sdNVP) for the HIV positive mother and her infant to 2.9% (95%CI: 2.8 – 3.0%) when the 
mother either received triple regimen for ART and a combination of AZT from 14 weeks of 
gestation, sdNVP in labour and stat dose of Tenofovir (TDF) and Emtritabine (FTC) post-
delivery for ARVP in the same region  (Moodley, Parboosing, & Moodley, 2013). Ayouba et 
al. (2003) however reported a lower MTCT risk of 10.6% (5.1-16.0) for a NVP-based 
PMTCT programme in 3 health facilities in Cameroon (Ayouba et al., 2003).  Reported 
results also suggest that in comparison with single or dual ARVs, MTCT risk was lower 
when HIV positive pregnant women receive triple regimen for ARVP or ART (Moodley et 
al., 2013; Torpey et al., 2012). Findings from Saint Camille Medical Centre Ouagadougou 
Burkina Faso suggests that  complete eMTCT is achievable when HIV positive pregnant 
women are on ART and their infants had replacement feeding (MTCT risk at 6 months in this 
category of mother-infant pair was found to be 0.0%) (Sagna et al., 2015).  These studies also 
revealed that even though PMTCT services are available at health facilities, not all mothers 
receive interventions (Coetzee et al., 2005; Torpey et al., 2012) .  
2.6.2 PMTCT programme evaluation: Nigeria  
Nigerian researchers conducted formative research between 2001 and 2002 at the 
commencement of PMTCT programme in the country (Agboghoroma et al., 2013). This was 
followed by operational research three years later (2005) using the 11 tertiary health facilities 
that were offering the PMTCT services in the country at that time (Agboghoroma et al., 
2013). The evaluation concluded that there was high uptake of HTC (77.8%); 63.1% of HIV 
positive pregnant women received ARVP. MTCT risk was found to be 3-5% even though 
less than 10% of women accessed this service (Galadanci et al., Undated). In general, only 
60% of pregnant women attended ANC while less than 40% of pregnant women deliver in 
health facilities while the rest deliver at home (National Population Commission (NPC) 
[Nigeria] & ICF International, 2014).   
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Small scale facility-level studies conducted in Nigeria revealed that the highest MTCT risk of 
33.3% - 37.5% was also recorded when sdNVP was used for ARVP (Chama, Gashau, & 
Oguche, 2007; Agboghoroma, Audu & Iregbu, 2015)  while  the lowest risks were observed 
when HIV positive pregnant woman were on lifelong ART or triple regimen and their infants 
got ARVP (Ben & Yusuf, 2014; Chama et al., 2010; Esene & Omoigberale, 2012; Kalu et al., 
2014; Isah et al., 2016). Chama, Gashau, & Oguche (2007) and Okafor et al. (2014) also 
reported complete eMTCT (MTCT risk of 0.0%) in HIV positive pregnant Nigerian women 
that were on ART. While the infants in the Chama, Gashau, & Oguche (2007) study were 
bottle fed, over 90% of the HEIs in the latter study were exclusively breastfed (Chama, 
Gashau, & Oguche, 2007; Okafor et al., 2014). Sagay et al. (2015) found pregnant women on 
lifelong ART before pregnancy to be at lower risk than those that started during pregnancy or 
at delivery. MTCT risk is also lower when only HIV positive pregnant women receive ARVP 
when compared to when HEIs alone received ARVP (Anoje et al., 2012; Chukwuemeka et 
al., 2014). The study conducted at Nnamdi Azikwe University Teaching Hospital suggests 
that breastfed infants are at higher risk of contracting HIV from their mothers than those not 
breastfed (Ikechebelu et al., 2011).   
Overall these studies prove the effectiveness and feasibility of PMTCT in resource poor 
countries: HIV positive pregnant women who received no or partial PMTCT interventions 
were more likely to give birth to HIV positive infants compared with those who received full 
PMTCT interventions (Azcoaga-Lorenzo et al., 2011; Afe et al., 2011).  
These studies assessed the effectiveness of the PMTCT programme by determining the HIV 
status of HEIs and other elements of the PMTCT service provision. Factors impeding service 
delivery such as lack of adequate follow up; lack of adequate training for staff etc. were 
equally highlighted while they recommend the need to replicate studies in other health 
facilities. A range of methodologies were adopted in evaluating PMTCT effectiveness; these 
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include cross sectional, retrospective and prospective cohort studies, case control study and 
analysis of EID records/HIV DNA PCR result. None of these studies were nationally 
representative.  
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3.0 METHODOLOGY 
This chapter describes the study setting, study population, ethical considerations, sampling 
and data collection procedures and data analysis methods. 
3.1 Study design 
This study was a retrospective record review and analysis of routine individual-level patient 
data collected in facility-based registers (ANC, PMTCT/HTC and EID/Infant follow up 
records) during the study periods (2008-2014) at Specialist Hospital (SH), Yola and Federal 
Medical Centre (FMC), Yola.  
3.2 Study setting 
The two health facilities in Adamawa State were purposively selected because the student 
worked with the consortium - Strengthening Integrated Delivery of HIV/AIDS Services 
(SIDHAS) that supported PMTCT services in the state and it was easy to obtain approval to 
access patient records. Background information about the two health facilities is summarized 
in table 3.1 below. 
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Table 3.1: Data collection sites’ background information 
Background Information SH Yola FMC Yola 
Category of Health Facility Secondary Tertiary 
Local Government Area (LGA) Yola North Yola South 
Date of antiretroviral therapy (ART)/PMTCT 
Services Commencement 
September, 2007 January, 2008 
1
ART client load as at December 2014 4,043 4,694 
1, 2, 3
 Antenatal (ANC) HIV prevalence 4% 3% 
Programme support (Presidents 
Emergency Plan for AIDS Relief 
(PEPFAR) - funded HIV/AIDS 
Programme implemented by a 
consortium led by Family Health 
International (FHI 360). 
2007-2011 
 
Global HIV/AIDS Project in Nigeria 
(GhAIN) 
2011-2016 
Strengthening Integrated Delivery of 
HIV/AIDS Services (SIDHAS) 
Other Services rendered 
ANC, General outpatient and specialist 
service 
1
Routine service data 
2 
(Bashorun et al., 2014) 
3 
(Federal Ministry of Health, 2010b) 
 
In addition to the reasons cited above, these health facilities were chosen because they have 
the highest patient load and antenatal clinic (ANC) attendance rates in the state, thus 
providing a large pool of pregnant women and by extension HIV positive pregnant women 
and their HEIs. They are also accessible by road. The facilities render services to pregnant 
women and HEIs following the cascade of events shown in Appendix 1 and 
prophylaxis/treatment protocol summarized in section 2.3 and Appendix 2. In conducting 
HIV Deoxyribonucleic Acid Polymerase Chain Reaction (DNA PCR) testing, the dried blood 
spot (DBS) samples of HEIs are collected using Lasec® DBS Collection kits with 5 spots and 
couriered to a DNA PCR testing facility (Federal Medical Centre, Jalingo; uses Roche® 
brand of PCR machine) located approximately 167 kilometers away from the two health 
facilities. The average turnaround time (TAT) for test results was projected to be three weeks 
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and caregivers are typically advised to return in four weeks to receive the DNA PCR test 
results.  
3.3 Study population 
The study population included the individual-level patient data from six sample groups (see 
table 3.2 below for detailed sample group and the reason for choice of each group) 
Table 3.2: Sample group and the reason for choice of each group 
S/N Group Reason 
1 
All pregnant women that attended ANC for the first 
time between 2008 and 2014 in the two health 
facilities. 
Denominator for uptake of 
HTC 
2 
All pregnant women who tested for HIV during first 
ANC visit 
Numerator for uptake of HTC 
and denominator for Maternal 
HIV positivity rate 
3 
All pregnant women that tested positive for HIV 
during first ANC visit between 2008 and 2014 in the 
two health facilities 
Numerator for maternal HIV 
positivity rate and 
denominator for ART/ARVP 
uptake 
4 
All pregnant women who received ARVs (either for 
prophylaxis or treatment) 
Numerator for ART/ARVP 
uptake 
5 
All HEIs (aged 4 weeks to >12 months) that tested for 
HIV between 2008 and 2014 
Denominator for MTCT risk 
6 
All HEIs (aged 4 weeks to >12 months) with HIV 
positive DNA PCR results between 2008 and 2014 
Numerator for MTCT risk 
 
The first and second groups were used to establish the uptake of HTC. The third and fourth 
groups were used to establish the uptake of maternal ART/ARVP while fifth and sixth groups 
were used to establish the risk of MTCT in the two health facilities. 
3.4 Sampling procedure 
For all objectives all individual-level patient data recorded using facility-based registers 
during the study period were used. There was no sampling as all available records with data 
were used. This approach was taken to increase the sample size, given that routine data may 
be incomplete or inaccurate; thus sampling may reduce final sample size.  
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3.5 Data collection and processing 
Data were collected for the six groups of women highlighted in table 3.2. Three Microsoft 
Excel-based data collection tools (DCTs) were used to manually extract information for all 
sample groups in accordance with Appendix 6 (see Appendix 7, 8 and 9 for DCTs). These 
tools were piloted in two health facilities similar to the study sites prior to their use for the 
main data collection. Some modifications were eventually made to these tools based on the 
observations and feedbacks from the pilot. DCT1 was used to collect information on sample 
groups 1 and 2 (2 independent data collectors were employed to count this data to avoid 
mistakes /and for validity), DCT 2 for sample groups 3 and 4 and DCT 3 for sample groups 5 
and 6. All HEIs and all HIV positive pregnant women were given unique identifiers. 
Manually extracted information was later entered into a pass word protected electronic 
database that was accessible to the student and data collectors during the period of data 
collection. Trained data collectors with experience in patient record management were used 
for the data collection process. Use of these DCTs ensured uniformity of collected data.  
3.6 Analysis 
Data analyses were performed using STATA 14.2 (Stata, 2017). The proportion of first ANC 
attendees that accepted HTC and maternal HIV positivity rate among those that accepted 
HTC as well as the associated 95% CI was estimated. Frequency counts and proportions were 
estimated for the following categorical variables: pregnant women’s age in years (15-24, 25-
34, 35-44, 45 and above), parity (0-4, >4), gestation age (14 -27 and 28 and above weeks), 
marital status (single, married, widowed, separated, divorced), educational level (none, 
primary, senior secondary, qur'anic, junior secondary, post-secondary) and occupational 
status (unemployed, employed, student, retired). Proportions were calculated for uptake of 
ART/ARVP among HIV positive pregnant women and the type of ARVs used (ART, Triple 
Regimen, AZT/3TC, AZT, NVP). Simple and multiple logistics regression were carried out 
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and resultant odds ratio or adjusted odds ratios estimated to determine associations between 
pregnant women’s age, gestation age, parity, marital status, educational level, occupational 
status, hospital and year and uptake of ART or ARVP based on the categorization highlighted 
above.  
 
Frequency counts (and proportions) of tested HEI’s gender (male, female), age (4 weeks -2 
months, >2months – 6 months and >6 months – 12 months, and >12 months) infant feeding 
option (exclusive breastfeeding, mixed feeding and not breastfed), reason for PCR (first test 
for healthy exposed infant, first test for sick infant and problem with first test) and maternal 
ART/ARVP and infant prophylaxis were calculated. Overall MTCT risk (with 95% 
confidence interval) and median facility TAT (with interquartile range) were calculated. 
MTCT risk (with 95% confidence interval) by age (4 weeks -2 months, >2months – 6 months 
and >6 months – 12 months, and >12 months), feeding option (exclusive breastfeeding, 
replacement feeding and mixed feeding), intervention (mother alone, infant alone, either 
mother or infant, both mother and infant) and PMTCT protocol period (period 1, transitional 
phase and period 2) were also estimated. Simple and multiple logistic regression analysis 
were then performed and odds ratio compared based on gender, HEI age of testing, 
intervention received, feeding option (based on earlier stated categorizations), hospital and 
year. P-values were estimated and a p-value of <0.05 was considered as statistically 
significant, non-overlap of confidence intervals (CIs) was also considered as statistically 
significant. In selected instances where CIs overlap, CI difference and p-value were estimated 
to establish statistical significance. The difference was regarded as significant if the CI did 
not contain zero. The STATA procedure that was used to estimate the proportions in this 
thesis does not respect that the estimates have to be between 0.0% and 100.0%. In cases 
where the estimate was extreme or where there was an uncertainty in the estimation, the 
http://etd.uwc.ac.za
25 
 
confidence intervals tended to go beyond the bounds of 0.0% and 100.0%. Confidence 
intervals of proportions that were negative were therefore converted to zero percent while 
those that were above 100 percent were converted to 100 percent (Stark, 2017). Also in 
instances where point estimate for proportion was either 0.0% or 100.0%, STATA did not 
estimate confidence intervals.  Details of the data analysis plan are available in appendix 10. 
Table 3.3 shows the assumptions that were made for the analyses. 
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Table 3.3: Analysis assumptions 
Objectives/Indicator Definition Assumptions Denominator Numerator 
Objective 1 
Determine the uptake of 
HTC by pregnant women 
attending ANC for the first 
time in the most recent 
pregnancy 
Proportion of pregnant 
women that attended ANC 
for the first time in the most 
recent pregnancy that tested 
for HIV. 
Pregnant women who tested 
for HIV all came for the first 
visit to this facility 
There is no time lag between 
1
st
 visit and 1
st
 HIV test 
 
Total number of pregnant women that 
attended ANC for the first time in this 
pregnancy 
Total number of 
pregnant women that 
tested for HIV during 
their first visit 
Objective 2 
Maternal/Antenatal HIV 
positivity rate during 
pregnancy 
Proportion of first ANC 
attendees that accepted HIV 
testing that tested HIV 
positive 
Results were obtained for all 
pregnant women that tested 
for HIV 
Total number of pregnant women that tested 
for HIV during the first ANC visit 
Total number of 
pregnant women that 
tested positive for HIV at 
their first visit. 
Objective 3 
Determine the uptake of 
maternal ART/ARVP 
amongst HIV positive 
pregnant women 
Proportion of ANC 
attendees who tested  HIV 
positive at their first visit 
that received ARVs (either 
for prophylaxis or 
treatment) 
All pregnant women that 
tested HIV positive and 
started on ARVs received 
their ARVs at the same 
facility where they were 
diagnosed to be HIV positive 
Total number of pregnant women that tested 
positive for HIV at the first ANC visit 
Total number of 
pregnant women that 
received ARVs (either 
for prophylaxis or 
treatment) 
Objective 4 
Determine turnaround time 
Time interval (in days) 
between when a DBS 
sample was collected from 
HEI and when the DNA 
PCR result was returned to 
the health facility. 
 
Only tests with both the dates 
when DBS sample was 
collected and when the DNA 
PCR result was returned to 
the health facility were 
included in the analysis 
 
Only samples collected 
between January 2008 and 
December 2014 were 
included in the analysis  
 
 
Not Applicable Not applicable 
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Objectives/Indicator Definition Assumptions Denominator Numerator 
Objective 4 
Overall MTCT risk 
Proportion of tested HIV 
exposed babies that tested 
HIV positive 
 
All second tests/repeat tests 6 
weeks post cessation of 
breastfeeding (89 in number) 
that cannot be longitudinally 
linked with the first tests 
were excluded from all 
analysis 
 
For longitudinally linked 
results, if an infant test HIV 
negative at first test and HIV 
positive at second testing. 
The HIV positive result was 
used in the analysis 
Total number of HEIs that tested for HIV. 
Total number of HEIs 
that tested HIV positive 
Objective 5 
Determine the MTCT risk 
at ages 4 weeks to 2 
months, >2months – 6 
months, >6 months to 12 
months and >12 months. 
 
 
An infant with first and 
second test results that fall 
within different age brackets 
was analyzed twice. 
 
Note: all equivocal results 
were left out of numerator 
and denominator 
Total number of PCR results 
Total number of HIV 
positive PCR result 
Objective 6 
Compare the MTCT risk by 
receipt/non-receipt of 
antiretroviral drugs 
(prophylaxis versus 
treatment) amongst HIV 
positive mothers 
 
 
For longitudinally linked 
results, if an infant test HIV 
negative at first test and HIV 
positive at second testing. 
The HIV positive result was 
used in the analysis 
Total number of PCR results 
Total number of HIV 
positive PCR result 
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Objectives/Indicator Definition Assumptions Denominator Numerator 
Objective 7 
Compare the MTCT risk by 
breastfeeding option 
(exclusively breast fed, 
mixed fed and not breastfed 
at all). 
 
 
For longitudinally linked 
results, if an infant test HIV 
negative at first test and HIV 
positive at second testing. 
The HIV positive result was 
used in the analysis 
Total number of PCR results 
Total number of HIV 
positive PCR result 
Objective 8 
Compare MTCT risk during 
two  periods of PMTCT 
protocol policy changes and 
the transitional period 
 
If the first test is negative and 
the 2
nd
 test is positive the 2
nd
 
test results was used to 
calculate MTCT risk if it 
falls within this period 
Total number of PCR results 
Total number of HIV 
positive PCR result 
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3.7 Validity 
 
Selection bias at the health facility level was avoided by the review of all available data. 
Records of a total of 62,224 pregnant women (FMC Yola = 14,892; SH Yola = 47,332) were 
reviewed while that of HEIs was 1,809 (FMC Yola = 832, SH Yola= 977). The study is 
however biased towards clients that visited the two health facilities. Data collectors were 
trained and uniform tools were used in order to reduce measurement bias. Also 
nomenclatures used in the tools in most cases were the same as those contained in the 
registers and forms. The student supervised the data collectors to ensure that they functioned 
according to the standardized operating procedure that the student developed for this study. 
The student also checked ten percent of the data collected by data collectors for accuracy. 
3.8 Reliability 
To improve reliability of the study, the DCTs were tested for intra-data-collector and inter-
data-collector reliability prior to use for data collection. Also data collectors were trained 
while entries by these data collectors were randomly checked by the student for accuracy and 
completeness. To check for reliability, data was recollected for 10% of participants using the 
same set of DCTs, the collected data was then cross-checked by the student with the first set 
of data collected in order to confirm that they closely match. In order to assess inter-observer 
bias between two trained data collectors, the two data collectors extracted information from 
the same set of records. The agreement level between the two data collections was 88% 
which is within the acceptable range of 81 – 100% (McHugh, 2012). 
3.9 Generalizability 
While the result of this study may not be statistically generalizable to health facilities within 
the North Eastern sub region of Nigeria as a representative sample of health facilities was not 
selected, the problems identified may be similar to those experienced in health facilities with 
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similar service conditions to the health facilities under investigation. These health facilities 
include all the other eighteen secondary health facilities in Adamawa State offering PMTCT 
services as well as ninety three other secondary and tertiary health facilities within the North 
Eastern sub region of Nigeria with similar maternal/antenatal HIV positivity profile, 
individuals with poor access to education, poorly resourced healthcare infrastructure and high 
patient to healthcare worker ratio. 
3.10 Ethics and legal consideration  
Ethics approval for this protocol was sought from the Senate Research Committee of the 
University of the Western Cape while permission to access patients’ records was obtained 
from the research ethics committee of the two health facilities involved in this study and the 
State Ministry of Health (SMoH) (see Appendix 11, 12, 13 and 14 for approvals). No 
individual patient-level consent was obtained and no harm to patients is anticipated as the 
data collection involved retrospective review of routine facility-level data. Names of 
participants were not extracted; personal identifying information of participants were only 
available to the data collectors and the student but were not documented. All collected 
information were kept in a locked cupboard (for hard copies) and  a password protected 
computer (for electronic copies); also the final analyses and results only report on aggregated 
data thereby protecting the identities of the study participants. Findings from this study were 
made available to the SMoH, research ethics committee and PMTCT service coordinator in 
the two health facilities as well as FHI360 which is the implementing partner/non-
governmental organization supporting service delivery at these two health facilities. 
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4.0 RESULTS 
This chapter summarizes the results of this study in line with the study objectives. 
4.1 Objective 1: Uptake of HTC by pregnant women attending ANC for the 
first time in the most recent pregnancy 
This indicator was defined in accordance with Table 3.2. 
Tables 4.1 and 4.2 below show the uptake of HTC among first ANC attendees and maternal 
HIV positivity rates respectively disaggregated by year for the two health facilities used for 
this study. A total of 62,224 pregnant women attended ANC for the first time between 2008 
and 2014 out of which 47,217 (75.9%) accepted HIV testing and counselling. While SH Yola 
had more ANC attendees than FMC Yola, uptake of HTC in FMC Yola was higher than that 
of SH Yola ([12,897/14,892] 86.6% Vs [34,320/47,332] 72.5%). 
Table 4.1: Uptake of HTC among first ANC attendees (N = 62,224) 
Year 
FMC Yola SH Yola Total 
n (%) 95% CI n (%) 95% CI n (%) 95% CI 
2008 1,360 (77.3%) 65.4% - 89.1% 4,005 (56.7%) 44.1% - 69.3% 5,365 (60.8%) 49.9% - 71.7% 
2009 3,034 (92.3%) 88.7% - 95.9% 5,606 (78.9%) 72.1% - 85.7% 8,640 (83.1%) 77.7% - 88.6% 
2010 2,134 (88.5%) 79.5% - 97.6% 4,004 (70.9%) 62.5% - 79.4% 6,138 (76.2%) 68.7% - 83.7% 
2011 1,550 (82.3%) 76.1% - 88.4% 3,991 (63.7%) 51.3% - 76.1% 5,541 (68.0%) 57.8% - 78.2% 
2012 1,640 (82.8%) 74.1% - 91.6% 4,963 (75.4%) 71.0% - 79.7% 6,603 (77.1%) 73.1% - 81.1% 
2013 1,767 (90.1%) 85.6% - 94.5% 5,527 (79.1%) 72.3% - 86.0% 7,294 (81.5%) 75.9% - 87.1% 
2014 *1,412 (87.8%) 83.3% -92.2% 6,224 (81.0%) 74.9% - 87.1% 7,636 (82.2%) 77.1% - 87.2% 
Total 12,897 (86.6%) 83.8% - 89.4% 34,320 (72.5%) 68.7% - 76.3% 47,217 (75.9%) 74.3% - 77.5% 
N= number of first ANC attendees  
n= number of pregnant first ANC attendees that accepted HIV testing and counselling                            
*there was no HTC in FMC Yola in December 2014 due to industrial action by health workers  
95% CI = 95% confidence interval 
 
4.2 Objective 2: Maternal/Antenatal HIV positivity rate 
This indicator was defined in accordance with Table 3.2. 
The overall maternal HIV positivity rate for the two health facilities was 3.1% (1,475 
pregnant women out of 47,217 pregnant women that tested for HIV). The maternal HIV 
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positivity rate for FMC Yola was 2.9% [372/12,897] (95%CI 2.5% - 3.3%) while that of SH 
Yola was 3.2% [1,103/34,320] (95%CI: 2.8% - 3.6%).  
Table 4.2: HIV positivity rate among pregnant women that tested for HIV (N = 47,217) 
Year 
FMC Yola SH Yola Total 
n (%) 95% CI n (%) 95% CI n (%) 95% CI 
2008 58 (4.3%) 3.4% - 5.1% 239 (6.0%) 5.1% - 6.8% 297 (5.5%) 4.8% - 6.2% 
2009 103 (3.4%) 2.7% - 4.1% 245 (4.4%) 3.8% - 4.9% 348 (4.0%) 3.6% - 4.5% 
2010 66 (3.1%) 1.6% - 4.6% 148 (3.7%) 3.1% - 4.3% 214 (3.5%) 2.8% - 4.1% 
2011 37 (2.4%) 1.6% - 3.2% 108 (2.7%) 2.1% - 3.3% 145 (2.6%) 2.1% - 3.1% 
2012 45 (2.7%) 1.9% - 3.6% 179 (3.6%) 2.8% - 4.4% 224 (3.4%) 2.7% - 4.0% 
2013 29 (1.6%) 1.2% - 2.1% 101 (1.8%) 1.4% - 2.2% 130 (1.8%) 1.5% - 2.1% 
2014 34 (2.4%) 1.6% - 3.2% 83 (1.3%) 1.0% - 1.7% 117 (1.5%) 1.2% - 1.9% 
Total 372 (2.9%) 2.5% - 3.3% 1,103 (3.2%) 2.8% - 3.6% 1,475 (3.1%) 3.0% - 3.3% 
N= number of pregnant women that accepted HIV testing and counselling 
n= number of pregnant women that accepted HIV testing and counselling that tested HIV positive 
 
Graphical trends of uptake of HTC and HIV positivity rates for FMC Yola, SH Yola and the 
two health facilities combined are presented in figures 4.1, 4.2 and 4.3 respectively. The 
lowest uptake of HTC across the two health facilities was in 2008 (combined uptake of 
60.8% [5,365/8,824]) while the highest uptake was in 2009 (combined uptake of 83.1% 
[8,640/10,391). There was a general decline in HIV positivity rate from 2008 to 2014 (5.5% 
[297/5,365] to 1.5% [117/7,636]), there was however a slight rise in HIV positivity rate in 
2012 (3.4% [224/6,603]). 
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Figure 4.1: Trend of uptake of HTC and HIV positivity rate for FMC Yola 
 
 
0.0%
1.0%
2.0%
3.0%
4.0%
5.0%
6.0%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
2008 2009 2010 2011 2012 2013 2014
Uptake of HTC
HIV Positivity Rate
http://etd.uwc.ac.za
34 
 
Figure 4.2: Trend of uptake of HTC and HIV positivity rate for SH Yola 
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Figure 4.3: Trend of uptake of HTC and HIV positivity rate for the two health facilities 
combined 
 
 
4.2.1 Baseline characteristics of HIV positive pregnant women 
Table 4.3 below shows the baseline characteristics of the 1,475 pregnant women that tested 
HIV positive over the seven year period (2008 – 2014).  Most (46.0%) of the women were 
between the ages of 25-34 years; most (54.0%) of them were also in second trimester at the 
time of first attendance.  The gravida and parity for most of the women was between 0 and 4 
and available data showed that majority of women were married and had attained senior 
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Table 4.3: Socio-demographic characteristics of HIV positive pregnant women from 
2008 -2014 (N=1475) 
Variable 
FMC Yola SH Yola Total 
n (%) n (%) n (%) 
Age 15-24 years 42 (11.3%) 373 (33.8%) 415 (28.2%) 
 
25-34 years 105 (28.2%) 574 (52.0%) 679 (46.0%) 
 
35-44 years 14 (3.8%) 91 (8.3%) 105 (7.1%) 
 
45 and above 0 (0.0%) 2 (0.2%) 2 (0.1%) 
 
Missing 211 (56.7%) 63 (5.7%) 274 (18.6%) 
 
Total 372 (100.0%) 1,103 (100.0%) 1,475 (100.0%) 
Gestation Age <14 weeks 8 (2.2%) 120 (10.9%) 128 (8.7%) 
 
14 -27 weeks 79 (21.2%) 717 (65.0%) 796 (54.0%) 
 
28 weeks and above 31 (8.3%) 178 (16.1%) 209 (14.2%) 
 
Missing 254 (68.3%) 88 (8.0%) 342 (23.2%) 
 
Total 372 (100.0%) 1,103 (100.0%) 1,475 (100.0%) 
Gravida 0-4 101 (27.2%) 814 (73.8%) 915 (62.0%) 
 
>4 23 (6.2%) 222 (20.1%) 245 (16.6%) 
 
Missing 248 (66.7%) 67 (6.1%) 315 (21.4%) 
 
Total 372 (100.0%) 1,103 (100.0%) 1,475 (100.0%) 
Parity 0-4 113 (30.4%) 937 (85.0%) 1,050 (71.2%) 
 
>4 11 (3.0%) 93 (8.4%) 104 (7.1%) 
 
Missing 248 (66.7%) 73 (6.6%) 321 (21.8%) 
 
Total 372 (100.0%) 1,103 (100.0%) 1,475 (100.0%) 
Marital Status Single 1 (0.3%) 6 (0.2%) 7 (0.5%) 
 
Married 55 (14.8%) 151 (13.7%) 206 (14.0%) 
 
Widowed 2 (0.5%) 6 (0.5%) 8 (0.5%) 
 
Separated 1 (0.3%) 3 (0.3%) 4 (0.3%) 
 
Divorced 1 (0.3%) 2 (0.5%) 3 (0.2%) 
 
Missing 312 (83.9%) 935 (84.8%) 1,247 (84.5%) 
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Variable 
FMC Yola SH Yola Total 
n (%) n (%) n (%) 
 
Total 372 (100.0%) 1,103 (100.0%) 1,475 (100.0%) 
Educational 
Level 
None 8 (2.2%) 9 (0.8%) 17 (1.2%) 
 
Primary 12 (3.2%) 24 (2.2%) 36 (2.4%) 
 
Junior Secondary 4 (1.1%) 1 (0.1%) 5 (0.3%) 
 
Senior Secondary 18 (4.8%) 71 (6.4%) 89 (6.0%) 
 
Post-Secondary 12 (3.2%) 24 (2.2%) 36 (2.4%) 
 
Qur'anic 3 (0.8%) 39 (3.5%) 42 (2.9%) 
 
Missing 315 (84.7%) 935 (84.8%) 1,250 (84.8%) 
 
Total 372 (100.0%) 1103 (100.0%) 1,475 (100.0%) 
Occupational 
Status 
Unemployed 31 (8.3%) 119 (10.8%) 150 (10.2%) 
 
Employed 18 (4.8%) 32 (2.9%) 50 (3.4%) 
 
Student 2 (0.5%) 2 (0.2%) 4 (0.3%) 
 
Missing 321 (86.3%) 950 (86.1%) 1,271 (86.2%) 
 
Total 372 (100.0%) 1,103 (100.0%) 1,475 (100.0%) 
N= number of pregnant women that accepted HIV testing and counselling that tested HIV positive 
 
4.3 Objective 3: Uptake of maternal ART/ARVP amongst HIV positive 
pregnant women 
This indicator was defined in accordance with Table 3.2. 
Out of the 1,475 pregnant women that tested HIV positive, records about antiretroviral drug 
use were only available for 224 (15.2%) of the women –the other records were either missing 
or could not be longitudinally linked. The overall uptake of ART/ARVP among these women 
was 85.7% [192/224] (81.1% - 90.3%). The highest uptake was recorded in 2009 (100.0% 
[10/10]) while the lowest was in 2008 (76.5% [13/17]). ART/ARVP uptake for the other 
years as well as the trend of uptake is available in Table 4.4 and Figure 4.4 respectively. 
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Table 4.4: Uptake of ART/ARVP among HIV positive pregnant women (N=224) 
Year 
FMC Yola SH Yola Total 
n % 95% CI n % 95% CI n % 95% CI 
2008 No data No data 13 (76.5%) 55.6% -97.4% 13 (76.5%) 55.6% - 97.4% 
2009 No data No data 10 (100.0%) 
 
10 (100.0%) 
 
2010 15 (88.2%) 72.4% - *100.0% 10 (83.3%) 61.2% -*100.0% 25 (86.2%) 73.4% - 99.0% 
2011 11 (84.6%) 64.1% - *100.0% 5 (100.0%) 
 
16 (88.9%) 73.9% - *100.0% 
2012 No data No data 24 (88.9%) 76.7% -*100.0% 24 (88.9%) 76.7% -*100.0% 
2013 8 (100.0%) 
 
44 (88.0%) 78.9% -97.1% 52 (89.7%) 81.7% - 97.6% 
2014 14 (93.3%) 80.2% - *100.0% 38 (76.0%) 64.0% -88.0% 52 (80.0%) 70.1% - 89.9% 
Total 48 (90.6%) 82.6% - 98.6% 144 (84.2%) 78.7% - 89.7% 192 (85.7%) 81.1% - 90.3% 
N= number of HIV positive pregnant women with information on ARV prophylaxis use 
n = number of HIV positive pregnant women that received ARV prophylaxis 
* confidence limit was amended so that the confidence intervals are bound between 0.0 and 100.0%. 
         STATA did not estimate confidence intervals because point estimate was 100.0% 
 
Figure 4.4: Trend of ART/ARVP uptake among HIV positive pregnant women 
 
As shown in table 4.5 below most (60.9% [117/192]) of the pregnant women that received 
antiretroviral intervention got the triple regimen for PMTCT. This is followed by ART (for 
prevention and treatment) which was received by 19.8% [38/192] of the pregnant women.  
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Table 4.5: ARV regimen for women that received ARVs (2008 -2014) (N= 192) 
Regimen 
FMC Yola SH Yola Total 
n (%) n (%) n (%) 
sdNVP 0 (0.0%) 1 (0.7%) 1 (0.5%) 
AZT 1 (2.1%) 0 (0.0%) 1 (0.5%) 
AZT+3TC 0 (0.0%) 9 (6.3%) 9 (4.7%) 
AZT+3TC+sdNVP 11 (22.9%) 9 (6.3%) 20 (10.4%) 
Triple regimen (ARVP) 6 (12.5%) 111 (77.1%) 117 (60.9%) 
ART 24 (50.0%) 14 (9.7%) 38 (19.8%) 
Missing 6 (12.5%) 0 (0.0%) 6 (3.1%) 
Total 48 (100.0%) 144 (100.0%) 192 (100.0%) 
 
Summary of uptake of HTC, maternal HIV positivity rate and maternal ART/ ARVP uptake 
including missing data is presented in figure 4.5.  
http://etd.uwc.ac.za
40 
 
 
 
                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
62,224 pregnant women attended ANC for the 
first time in this pregnancy                                            
(FMC Yola = 14,892; SH Yola = 47,332) 
47, 217 (75.9%) of these pregnant women tested 
for HIV                                                                   
(FMC Yola = 12,897; SH Yola = 34,320) 
1,475 (3.1%) of the pregnant women that tested 
for HIV tested HIV positive                                                                  
(FMC Yola = 372; SH Yola = 1,103) 
192 (85.7%) of the HIV pregnant women with 
record on ARV use (224) received ARVs                                                                 
(FMC Yola = 48; SH Yola = 144) 
Record on ARV use 
missing/could not be 
longitudinally linked for 1,251 
(84.8%) pregnant women                                   
(FMC Yola = 319; SH Yola = 
932)    
            
 
 
Figure 4.5: Flow Chart for Uptake of HTC, maternal HIV positivity rate and maternal 
ART/ ARVP Uptake 
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4.3.1 Predictors of ART/ARVP uptake 
To establish factors that predict ART/ARVP uptake, simple and multiple logistic regressions 
analysis were carried out with resultant odds ratio estimated. From the simple regression 
analysis (see table 4.6) age, marital status and occupational status were found to be predictors 
of ART/ARVP uptake.  
All the variables listed in table 4.6 below were included in a multiple regression model. 
Parity was not included because of its high correlation of 0.9 with gravida. From this 
analysis, only age statistically predicted uptake of ART/ARVP. Women aged between 25-34 
years had three times (3.07) the odds to receive ART/ARVP than those aged 15-24 years. 
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Table 4.6: Factors associated with uptake of ART/ARVP with odds ratio using 
cumulative pooled data 
Variable 
 
Crude Odds 
Ratio 
95% CI 
P 
value 
Adjusted 
Odds Ratio 
95% CI 
P 
value 
Age 15-24 1.00 
  
1.00 
  
 
25-34 *3.40 1.53 - 7.55 0.00 *3.07 1.04 - 9.01 0.04 
 
35-44 3.23 0.68 - 15.23 0.14 2.65 0.32 - 22.13 0.37 
Gestation Age <14 weeks 1.00 
  
1.00 
  
 
14-27 weeks 1.62 0.54 - 4.83 0.39 2.41 0.55 - 10.54 0.24 
 
28 weeks 
and above 
2.05 0.53 - 7.96 0.30 1.75 0.31 - 9.69 0.52 
Gravida 1-4 1.00 
  
1.00 
  
 
>4 1..98 0.66 - 5.99 0.23 1.50 0.35 - 6.42 0.59 
Marital Status 
Single, 
Widowed, 
Separated, 
Divorced 
1.00 
  
1.00 
  
 
Married *3.23 1.20 - 8.69 0.02 1.97 0.50 - 7.75 0.33 
Educational 
Level 
None 1.00 
  
1.00 
  
 
Primary 0.67 0.15- 2.94 0.60 0.33 0.04 - 2.63 0.29 
 
Qur'anic 0.79 0.18- 3.34 0.74 0.57 0.08- 3.91 0.56 
 
Secondary 1.43 0.36 - 5.72 0.61 0.58 0.09 - 3.97 0.58 
 
Post-
Secondary 
1.00 
  
1.00 
  
Occupational 
Status 
Unemployed 1.00 
  
1.00 
  
 
Employed *10.54 1.39- 79.72 0.02 4.57 0.51- 40.62 0.17 
 
Student 0.66 0.07 - 6.58 0.72 1.00 1.00 
 
Hospital FMC Yola 1.00      
 SH Yola 0.56 0.20 – 1.52 0.25 1.10 0.21 – 5.70 0.91 
Year 2008 1.00   1.00   
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Variable 
 
Crude Odds 
Ratio 
95% CI 
P 
value 
Adjusted 
Odds Ratio 
95% CI 
P 
value 
 2009 1.00   1.00   
 2010 1.92 0.41 – 8.97 0.41 1.29 0.15 – 10.83 0.82 
 2011 2.46 0.39 – 15.63 0.34 1.61 0.12 – 20.95 0.72 
 2012 2.46 0.48 – 12.72 0.28 1.55 0.21 – 11.73 0.67 
 2013 2.67 0.66 – 10.85 0.17 1.84 0.32 – 10.57 0.50 
 2014 1.23 0.34 -  4.40 0.75 0.51 0.09 – 2.86 0.44 
*Statistically significant odds ratio      
 
4.4 Objectives 4-8: MTCT risk in general and DNA PCR test turnaround 
time, MTCT risk by age, by feeding option, by ARV use and by PMTCT 
protocol period 
4.4.1 Records used for EID-related analysis 
Given that personal identifiers were not collected, second tests (repeat tests six weeks post 
cessation of breastfeeding) conducted prior to August 2012 could not be longitudinally linked 
with first tests - the design of the EID register used prior to August 2012 did not allow for 
longitudinal linkage of the first and second test results. A total of 89 of these tests were 
excluded from all analyses. Also one test with missing reason for PCR test and another test 
with confirmation of first test (not recognized in the national testing algorithm) as the reason 
for testing were also excluded. 
‘First test for healthy exposed infant’, ‘first test for sick infant’ and ‘problem with first test’ 
indicators were taken as first EID test as per national algorithm and it was assumed there was 
no duplication of babies within the ‘problem with first test’ versus ‘first test for healthy 
exposed infant’ and ‘first test for sick infant’ groups. For ‘problem with first test’ to be 
conducted, the result of the first test must be indeterminate or missing. There was no 
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indeterminate test result and only 120 babies had missing results for both ‘first test for 
healthy exposed infant’ and ‘first test for sick infant’ compared to the 374 results available 
for infants with ‘problem with first test’ as the reason for HIV DNA PCR test. 
Of the 1,809 babies included in the final analysis only 1,651 (91.3%) had first HIV DNA 
PCR test results. Out of the 1,279 HEIs that were expected to have a second PCR test by 
virtue of their breastfeeding option (exclusively breastfed and mixed fed), only 35 (2.7%) of 
them had longitudinally linked second PCR test results.  It should be noted that information 
on feeding option was not available for 81 HEIs. 
4.4.2 Baseline characteristics and prophylaxis status for HIV exposed infants 
(2008 – 2014) 
Table 4.7 below summarizes the baseline characteristics of the 1,809 HIV exposed infants 
included in the analysis for this study. More than half of the babies were male (50.6%) and 
only 30.0% of the babies tested for HIV by the recommended age of 6 weeks. The 
commonest mode of feeding adopted by mothers at the time the infant was brought for testing 
(median age of 8 weeks) was exclusive breastfeeding (54.7%) while mixed feeding (16.0%) 
was the least common for the entire 7 years under review. 
Close to seventy percent (68.4%) of mothers of HEIs received either ART or ARVP while 
~65% of infants received sdNVP, sdNVP+AZT or NVP as prophylaxis for the entire 7 years 
under review.  
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Table 4.7: Baseline characteristics and prophylaxis status for HIV exposed infants (2008 
-2014) (N = 1809) 
Variable 
FMC Yola SH Yola Total 
n (%) n (%) n (%) 
Gender Male 426 (51.2%) 489 (50.1%) 915 (50.6%) 
 
Female 406 (48.8%) 488 (49.9%) 894(49.4%) 
 
Total 832 (100.0%) 977 (100.0%) 1,809 (100.0%) 
Age ≤6 weeks 306 (36.8%) 237 (24.3%) 543 (30.0%) 
 
>6 weeks to 2 months 166 (20.0%) 249 (25.5%) 415 (22.9%) 
 
>2months – 6 months 201 (24.2%) 279 (28.6%) 480 (26.5%) 
 
>6 - 12 months 112 (13.5%) 149 (15.3%) 261 (14.4%) 
 
>12 months 39 (4.7%) 43 (4.4%) 82 (4.5%) 
 
Missing 8 (1.0%) 20 (2.1%) 28 (1.6%) 
 
Total 832 (100.0%) 977 (100.0%) 1,809 (100.0%) 
Infant Feeding Option Exclusive breastfeeding 433 (52.0%) 557 (57.0%) 990 (54.7%) 
 
Not breastfed or 
Replacement feeding 
266 (32.0%) 183 (18.7%) 449 (24.8%) 
 
Mixed feeding 86 (10.3%) 203 (20.8%) 289 (16.0%) 
 
Missing 47 (5.7%) 34 (3.5%) 81(4.5%) 
 
Total 832 (100.0%) 977 (100.0%) 1,809 (100.0%) 
Reason for PCR 
First test for healthy 
exposed infant 
641 (77.0%) 762 (78.0%) 1,403 (77.6%) 
 First test for sick infant 19 (2.3%) 13 (1.3%) 32 (1.8%) 
 Problem with first test 172 (20.7%) 202 (20.7%) 374 (20.7%) 
 Total 832 (100.0%) 977 (100.0%) 1,809 (100.0%) 
Maternal ARVs ART 425 (51.1%) 179 (18.3%) 604 (33.3%) 
 ARVP 188 (22.6%) 182 (18.6%) 370 (20.4%) 
 *ART or Triple Regimen 86 (10.3%) 180 (18.4%) 266 (14.7%) 
 None 97 (11.7%) 134 (13.7%) 231 (12.8%) 
 Missing 36 (4.3%) 302 (30.9%) 338 (18.7%) 
http://etd.uwc.ac.za
46 
 
Variable 
FMC Yola SH Yola Total 
n (%) n (%) n (%) 
 Total 832 (100.0%) 977 (100.0%) 1,809 (100.0%) 
Type of Maternal 
ARVP 
AZT + 3TC and sdNVP 136 (72.3%) 44 (24.2%) 180 (48.7%) 
 AZT and sdNVP in labour 9 (4.8%) 29 (15.9%) 38 (10.3%) 
 Triple regimen 38 (20.2%) 82 (45.1%) 120 (32.4%) 
 sdNVP 3 (1.6%) 21 (11.5%) 24 (6.5%) 
 Unknown 2 (1.1%) 1 (0.6%) 3 (0.8%) 
 Missing 0 (0.0%) 5 (2.8%) 5 (1.4%) 
 Total 188 (100.0%) 182 (100.0%) 370 (100.0%) 
Infant ARVs sdNVP at birth 36 (4.3%) 0 (0.0%) 36 (2.0%) 
 
sdNVP at birth and AZT for 
4 weeks 
255 (30.6%) 132 (13.5%) 387 (21.4%) 
 NVP for 6 weeks 366 (44.0%) 394 (40.3%) 760 (42.0%) 
 Unknown 3 (0.4%) 0 (0.0%) 3 (0.2%) 
 None 122 (14.7%) 167 (17.1%) 289 (16.0%) 
 Missing (ARV Type) 5 (0.6%) 4 (0.4%) 9 (0.5%) 
 Missing (Prophylaxis use) 45 (5.4%) 280 (28.7%) 325 (18.0%) 
 Total 832 (100.0%) 977 (100.0%) 1,809 (100.0%) 
N= Total number of HIV Exposed Infants 
*Pregnant women took triple regimen either solely for PMTCT (ARVP) or as ART (both for PMTCT and their 
health). Documentation was not clear enough to delineate as ART or ARVP 
 
Summary of overall MTCT risk, MTCT risk segregated by age, breastfeeding option, 
ART/ARVP option and PMTCT protocol periods including missing data is presented in 
figure 4.6. It should be noted that records of HIV positive pregnant women were not 
longitudinally linked to that of their HEIs hence HEIs were not necessarily delivered by the 
pregnant women that tested positive during ANC. Information on mother and infant’s ARV 
use and breastfeeding option were however available in either or both the EID follow up  
register and PCR request and result form.
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1,809 HIV Exposed Infants (HEIs) 
(FMC Yola = 832; SH Yola = 977) 
 
1,651 HEIs had First PCR 
Test Result 
158 HEIs have missing 
PCR Test Result 
1,279 HEIs eligible for 
2
nd
 PCR Test 
35 HEIs had 2
nd
 PCR 
Test Result 
Eligibility of 81 HEIs could 
not be established due to 
missing breastfeeding option 
16 of the tests had both 
sample collection and 
return dates 
5 tests included in 
turnaround time 
(TAT) analysis 
11 samples 
collected in 
2015 
excluded 
1,293 of the tests had 
both sample collection 
and return dates (all 
included in turnaround 
time analysis) 
1,655 HEIs had either 1
st
 or 
2
nd
 PCR Test Result 
4 HEIs with missing 
1
st
 PCR Test Result 
had 2
nd
 PCR Test 
Result 
 160/1651 (9.7%) 
HEIs tested HIV 
positive 
74/892 (8.3%) HEIs 
Exclusively 
Breastfed, 
58/259 (22.4%) 
Mixed Fed, 
and 23/429 (5.4%) 
Not Breastfed tested 
HIV+ 
 
25/1,034 (2.4%) HEIs who received 
ARV prophylaxis (ARVP) with their 
mothers, 7/94 (7.4%) whose mother 
alone received ARVP, 4/42 (9.5%) who 
alone received ARVP and 83/170 
(48.8%) who did not receive ARVP 
neither did their mother receive tested 
HIV + 
 
58/353 (16.4%) HEIs 
born during Period 1, 
63/572 (11.0%) born 
during the 
Transitional Period, 
39/726 (5.4%) born 
during Period 2 tested 
HIV + 
15/499 (3.0%) HEIs aged ≤6 wks 
13/387 (3.4%) aged >6 wks - 2 
mons 
49/441 (11.1%) aged >2 mons - 6 
mons 
51/242 (21.1%) aged >6 - 12 mons 
30/86 (34.9%) aged >12 mons 
tested HIV + 
 
41/311 (13.2%) HEIs 
with missing ARV 
prophylaxis information 
for either mother or 
infant tested HIV + 
3/20 (15.0%) HEIs with 
missing age tested HIV 
positive (+) 
6/75 (8.0%) HEIs 
with missing 
breastfeeding option 
tested HIV+ 
Figure 4.6: Flow Chart for overall MTCT risk, MTCT risk segregated by age, breastfeeding option, ART/ARVP option and PMTCT protocol 
periods 
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4.4.3 Objective 4: Overall MTCT risk and turnaround time 
The overall MTCT risk for all HEIs with first HIV DNA PCR test result, between 2008 and 
2014 was 9.7% [160/1,651] (95% CI 8.3% - 11.1%) at median age of 8 weeks (IQR= 6-20). 
Although the overall MTCT risk for SH Yola was higher than that of FMC Yola, the 
difference was not statistically significant (95% CI difference = -4.4% - 1.2%; p=0.273) (see 
table 4.8). Except for the increase seen in 2009 (from 14.3% [7/49] to 17.9% [44/246]), 
MTCT risk generally declined over the 7 year period even though the decline between 
consecutive years was not statistically significant (see table 4.9) - the only exception to this is 
2011 versus 2012 (95% CI difference = 0.1% -8.1%). The median age across most of the 
years (5 out of 7) was 8 weeks (see table 4.10) 
The overall median turnaround time for the two health facilities was 48 days (IQR: 31-78; 
n=1,298). For the first three years reviewed (2008 -2010), median TAT was less than 40 
days. It however increased from 53 in 2011 to 133 in 2014 (see table 4.11).  
Table 4.8: Overall MTCT risk and turnaround time at median age of 8 weeks (N=1651) 
 
FMC Yola SH Yola Total 
 
n (%) 95% CI n (%) 95% CI n (%) 95% CI 
Overall MTCT 
Risk 
66 (8.8%) 6.8%-10.9% 94 (10.4%) 8.4%-12.4% 160 (9.7%) 8.3%-11.1% 
 
Median IQR Median IQR Median IQR 
Age in weeks 8 6-20 8 7-20 8 6 – 20 
Turn Around 
Time in Days 
48 (593) 33-75 48 (705) 30-81 48 (1,298) 31-78 
n = number of HIV exposed infants that tested HIV positive; IQR= interquartile range; ( ) number of EID tests 
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Table 4.9: Yearly trend of MTCT risk for FMC Yola and SH Yola at median age of 8 
weeks (N=1651) 
 
FMC Yola SH Yola Total 
Year n (%) 95% CI n (%) 95% CI n (%) 95% CI 
2008 2 (14.3%) *0.0%-33.3% 5 (14.3%) 2.5%-26.1% 7 (14.3%) 4.4%-24.2% 
2009 14 (13.3%) 6.8%-19.9% 30 (21.3%) 14.5%-28.1% 44 (17.9%) 13.1%-22.7% 
2010 16 (11.3%) 6%-16.5% 22 (15.9%) 9.8%-22.1% 38 (13.6%) 9.5%-17.6% 
2011 17 (9.4%) 5.1%-13.7% 14 (9.1%) 4.5%-13.6% 31 (9.3%) 6.1%-12.4% 
2012 4 (3.8%) 0.1%-7.4% 11 (6%) 2.5%-9.4% 15 (5.2%) 2.6%-7.7% 
2013 5 (5.6%) 0.8%-10.3% 9 (6.7%) 2.4%-10.9% 14 (6.2%) 3.1%-9.4% 
2014 8 (7.4%) 2.4%-12.4% 3 (2.5%) *0.0%-5.4% 11 (4.9%) 2.1%-7.7% 
Overall 66 (8.8%) 6.8%-10.9% 94 (10.4%) 8.4%-12.4% 160 (9.7%) 8.3%-11.1% 
N= Total number of HIV Exposed Infants 
* confidence limit was amended so that the confidence intervals are bound between 0 and 100%. 
 
Table 4.10: Yearly trend of median age of HEIs (with IQR) for FMC Yola and SH Yola 
 
FMC Yola 
 
SH Yola 
 
Total 
 
Year Median IQR Median IQR Median IQR 
2008 24.0 12-32 12 8-16 12 8-24 
2009 12.0 8-26 10 7-28 12 8-28 
2010 8.0 6-20 8 6-28 8 6-24 
2011 7.0 6-16 8 6-23 8 6-20 
2012 7.5 6-24 8 6-16 8 6-20 
2013 7.0 6-11 8 7-20 8 6-16 
2014 8.0 6-16 9 7-14 8 6-15 
Overall 8.0 6-20 8 7-20 8 6-20 
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Table 4.11: Yearly trend of TAT for FMC Yola and SH Yola (N=1298) 
 
FMC Yola SH Yola Total 
Year median (n) IQR median (n) IQR median (n) IQR 
2008 38.5 (14) 31-46 37 (35) 25.5-51 37 (49) 31-51 
2009 39.5 (106) 29-54 34 (141) 29-49 36 (247) 29-54 
2010 35 (130) 25.25-44.75 29 (135) 22-48 32 (265) 25-45 
2011 51 (179) 37.5-67 67 (154) 43-103 53 (333) 38-83 
2012 85 (61) 68-96 47 (137) 40-56 54.5 (198) 40-78 
2013 115 (13) 101-122 110 (25) 103-124 113 (38) 101.5-124 
2014 133 (90) 
44.25-
164.75 
133.5 (78) 109-172 133 (168) 76-172 
Overall 48 (593) 33-75 48 (705) 30-81 48 (1,298) 31-78 
N=Total number of EID tests 
n=number of EID tests 
 
4.4.4 Objective 5: MTCT risk by age 
Table 4.12 below shows the age-specific MTCT rate among HEIs. MTCT risk was lowest 
among infants aged 2 months and below (3.0% [15/499] - 3.4% [13/387]). The risk was 
11.1% [49/441] among those that were >2 months - 6 months while those that were older 
than 6 months had MTCT risk between 21.1% [51/242] and 34.9% [30/86]. From the yearly 
trend shown in Table 4.13, the lowest MTCT risks were among babies that were either 2 
months or younger and highest among those >12 months for most of the years. 
Table 4.12: MTCT risk by age (N=1675
+
) 
Age 
FMC Yola SH Yola Total 
n (%) 95% CI n (%) 95% CI n (%) 95% CI 
≤6 wks 7 (2.5%) 0.7% -4.4% 8 (3.6%) 1.1%-6.0% 15 (3.0%) 1.5%-4.5% 
>6 wks - 2 mons 5 (3.4%) 0.5%-6.3% 8 (3.3%) 1.1%-5.6% 13 (3.4%) 1.6%-5.2% 
>2 mons - 6 mons 23 (12.5%) 7.7%-17.3% 26 (10.1%) 6.4%-13.8% 49 (11.1%) 8.2%-14.0% 
>6 - 12 mons 21 (19.8%) 12.2%-27.4% 30 (22.1%) 15.1%-29.1% 51 (21.1%) 15.9%-26.2% 
>12 mons 10 (20.4%) 9.0%-31.8% 20 (54.1%) 37.8%-70.3% 30 (34.9%) 24.7%-45.0% 
Missing 1 (14.3%) *0.0%-42.3% 2 (15.4%) *0.0%-35.8% 3 (15.0%) *0.0%-31.1% 
Total 6 7 (8.7%) 6.7%-10.7% 94 (10.4%) 8.4%-12.4% 161 (9.6%) 8.2%-11.0% 
N = Total number of HIV Exposed Infants 
+ Infants with first and second test results that fall within different age brackets were analyzed twice. 
n = number of HIV exposed infants that tested HIV positive; wks = weeks; mons= months 
*confidence limit was amended so that the confidence intervals are bound between 0% and 100% 
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Table 4.13: Yearly trend of MTCT risk by age at FMC Yola and SH Yola (N=1675) 
Year 
≤6 wks >6 wks - 2 mons >2 mons - 6 mons >6 - 12 mons >12 mons Missing 
n (%) 95% CI n (%) 95% CI n (%) 95% CI n (%) 95% CI n (%) 95% CI n (%) 95% CI 
2008 0 (0.0%)  0 (0.0%)  5 (26.3%) 6%-46.7% 2 (25.0%) *0.0%-57.1% 0 (0.0%)  0 (0.0%)  
2009 3 (6.7%) *0.0%-14.0% 5 (7.8%) 1.2%-14.4% 15 (20.8%) 11.4%-30.3% 16 (33.3%) 19.8%-46.8% 5 (35.7%) 9.6%-61.8% 0 (0.0%) 
 
2010 5 (5.7%) 0.8%-10.5% 2 (3.2%) *0.0%-7.7% 8 (12.7%) 4.4%-21.0% 8 (16.7%) 6.0%-27.3% 15 (78.9%) 60.1%-97.8% 0 (0.0%) 
 
2011 1 (0.7%) *0.0%-2.2% 4 (6.0%) 0.2%-11.7% 8 (11.1%) 3.8%-18.4% 14 (28.6%) 15.8%-41.4% 4 (36.4%) 6.5%-66.2% 0 (0.0%) 
 
2012 3 (3.2%) *0.0%-6.8% 1 (1.5%) *0.0%-4.4% 5 (6.3%) 0.9%-11.7% 3 (7.5%) *0.0%-15.8% 2 (25.0%) *0.0%-57.1% 1 (33.3%) *0.0%-98.7% 
2013 0 (0.0%) 
 
1 (1.5%) *0.0%-4.4% 5 (8.6%) 1.3%-15.9% 5 (21.7%) 4.5%-39.0% 2 (22.2%) *0.0%-51.1% 1 (8.3%) *0.0%-24.7% 
2014 3 (4.1%) *0.0%-8.7% 0 (0.0%) 
 
3 (3.8%) *0.0%-8.1% 3 (11.5%) *0.0%-24.1% 2 (9.1%) *0.0%-21.4% 1 (50.0%) *0.0%-*100.0% 
Overall 15 (3.0%) 1.5%-4.5% 13 (3.4%) 1.6%-5.2% 49 (11.1%) 8.2%-14% 51 (21.1%) 15.9%-26.2% 30 (34.9%) 24.7%-45.0% 3 (15.0%) *0.0%-31.1% 
N = Total number of HIV Exposed Infants 
* confidence limit was amended so that the confidence intervals are bound between 0 and 100%. 
 STATA did not estimate confidence intervals because point estimate was 0.0% 
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4.4.5 Objective 6: MTCT risk by breastfeeding option 
The least MTCT risk was found among infants that were not breastfed (5.4%) [23/429] while 
the highest was found among mixed fed infants (22.4%) [58/259] (see details in table 4.14). It 
should be noted that information on feeding option was only available for 1,580 of HEIs. 
 
Table 4.14: MTCT risk by breastfeeding option at median age of 8 weeks (N=1655) 
Breastfeeding option 
FMC Yola SH Yola Total 
n (%) 95% CI n (%) 95% CI n (%) 95% CI 
Exclusive Breastfeeding 35 (9.1%) 6.2%-12.0% 39 (7.7%) 5.3%-10.0% 74 (8.3%) 6.5%-10.1% 
Mixed Feeding 18 (25.0%) 14.9%-35.1% 40 (21.4%) 15.5%-27.3% 58 (22.4%) 17.3%-27.5% 
Not Breastfed 10 (4.0%) 1.6%-6.4% 13 (7.3%) 3.5%-11.2% 23 (5.4%) 3.2%-7.5% 
Missing 4 (9.3%) 0.5%-18.1% 2 (6.3%) *0.0%-14.8% 6 (8.0%) 1.8%-14.2% 
Total 67 (8.9%) 6.9%-11.0% 94 (10.4%) 8.4%-12.4% 161 (9.7%) 8.3%-11.2% 
N= Total number of HIV Exposed Infants with either first or second EID test result 
n = number of HIV exposed infants that tested HIV positive 
* confidence limit was amended so that the confidence intervals are bound between 0 and 100%. 
4.4.6 Objective 7: MTCT risk by receipt of ART/ARVP  
At a median age of 8 weeks, MTCT risk was 2.4% [25/1,034] when mother-infant pairs 
received antiretroviral drugs for treatment, prophylaxis or both (ART/ARVP). MTCT risk 
was higher when infant alone received ART/ARVP compared to when mother alone did 
(9.5% [4/42] Vs 7.4% [7/94]; 95% CI difference = -8.2% - 12.4%; p=0.677) even though this 
difference was not statistically significant. MTCT risk was close to 50% when neither mother 
nor infant received ART/ARVP (48.8% [83/170]). 
In instances where mothers received ART/ARVP irrespective of whether HEIs received ARV 
prophylaxis or not, MTCT risk ranged from 1.9% [7/359] – 3.7% [7/191]. MTCT risk on the 
other hand was 41.5% [90/217] when mothers did not receive any ARVs. MTCT risk was 
lower in women who started ART during pregnancy when compared with those who started 
before (difference was not statistically significant - 95% CI difference = -1.1% - 4.1%; 
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p=0.326) while none of the mothers that received triple regimen (ARVP) for PMTCT 
delivered HIV positive infants. 
MTCT risk among infants who received prophylaxis irrespective of mother’s prophylactic 
option was 2.7% [30/1,098] while it was 34.4% [93/270] among those that did not. None of 
the infants who received sdNVP were HIV positive while infants who received daily dose of 
NVP for 6 weeks had a lower risk than those that received AZT+sdNVP (1.6% [11/667] Vs 
4.7% [18/384] ; p=0.003) (See details of MTCT risk in table 4.15). 
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Table 4.15: MTCT risk by receipt of ART/ARVP (2008 – 2014) (N=1,651) 
Receipt of ART/ARVP 
FMC Yola SH Yola Total 
N 95% CI N 95% CI n 95% CI 
ART/ 
ARV Prophylaxis 
Receipt (Mother and 
Infant Pair) 
Mother and Infant 
received 
15 (2.5%) 1.3%-3.8% 10 (2.3%) 0.9%-3.7% 25 (2.4%) 1.5%-3.4% 
Mother alone received 6 (14.0%) 3.5%-24.4% 1 (2.0%) *0.0%-5.8% 7 (7.4%) 2.1%-12.8% 
Infant alone received 4 (20.0%) 2.0%-38.0% 0 (0.0%) 
 
4 (9.5%) 0.5%-18.5% 
 
Neither mother nor 
infant received 
36 (56.3%) 44.0%-68.5% 47 (44.3%) 34.8%-53.8% 83 (48.8%) 41.3%-56.4% 
 
Mother received and 
infant missing 
3 (23.1%) *0.0%-46.9% 31 (12.6%) 8.4%-16.7% 34 (13.1%) 9.0%-17.2% 
 
Mother missing Infant 
received 
0 (0.0%) 
 
1 (5.3%) *0.0%-15.6% 1 (4.5%) *0.0%-13.5% 
 
Mother  missing Infant 
did not receive 
1 (50.0%) *0.0%-*100.0% 2 (50.0%) *0.0%-*100.0% 3 (50.0%) 6.1%-93.9% 
 
Mother received Infant 
missing 
0 (0.0%) 
 
0 (0.0%) 
 
0 (0.0%) 
 
 
Mother did not receive 
Infant missing 
1 (33.3%) *0.0%-98.7% 2 (100.0%) 
 
3 (60.0%) 12.0%-*100.0% 
 
Total 66 (8.8%) 6.8%-10.9% 94 (10.4%) 8.4%-12.4% 160 (9.7%) 8.3%-11.1% 
Maternal ARV/ART 
irrespective of infant 
prophylactic option 
ART 16 (3.8%) 2.0%-5.7% 2 (1.1%) *0.0%-2.7% 18 (3.0%) 1.6%-4.4% 
 
ARVP 2 (1.1%) *0.0%-2.6% 5 (2.8%) 0.4%-5.3% 7 (1.9%) 0.5%-3.4% 
 
ART or ARVP 3 (7.1%) *0.0%-15.0% 4 (2.7%) 0.1%-5.3% 7 (3.7%) 1.0%-6.3% 
 
No 41 (47.1%) 36.6%-57.7% 49 (37.7%) 29.3%-46.1% 90 (41.5%) 34.9%-48% 
 
Missing 4 (22.2%) 2.4%-42.0% 34 (12.6%) 8.6%-16.6% 38 (13.2%) 9.3%-17.1% 
 
Total 66 (8.8%) 6.8%-10.9% 94 (10.4%) 8.4%-12.4% 160 (9.7%) 8.3%-11.1% 
Timing of Maternal 
ART 
Before 13 (4.3%) 2.0%-6.7% 1 (0.8%) *0.0%-2.3% 14 (3.3%) 1.6%-5.0% 
 
During 3 (2.5%) *0.0%-5.4% 0 (0.0%) 
 
3 (1.8%) *0.0%-3.9% 
 
Missing 
  
1 (16.7%) *0.0%-49.4% 1 (16.7%) *0.0%-49.4% 
 
Total 16 (8.8%) 6.8%-10.9% 2 (10.4%) 8.4%-12.4% 18 (9.7%) 8.3%-11.1% 
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Receipt of ART/ARVP 
FMC Yola SH Yola Total 
N 95% CI N 95% CI n 95% CI 
Maternal ARVP type 
irrespective of infant 
prophylactic option 
sdNVP 0 (0.0%) 
 
2 (10.5%) *0.0%-24.8% 2 (9.1%) *0.0%-21.4% 
 
AZTsdNVP 0 (0.0%) 
 
1 (3.7%) *0.0%-11.0% 1 (2.9%) *0.0%-8.5% 
 
AZT3TCsdNVP 2 (1.5%) *0.0%-3.6% 1 (1.5%) *0.0%-3.6% 3 (1.7%) *0.0%-3.6% 
 
Triple regimen 0 (0.0%) 
 
0 (0.0%) 
 
0 (0.0%) 
 
 
Unknown 0 (0.0%) 
 
0 (0.0%) 
 
0 (0.0%) 
 
 
Missing 
  
1 (20.0%) *0.0%-59.3% 1 (20.0%) *0.0%-59.3% 
 
Total 2 (8.8%) 6.8%-10.9% 5 (10.4%) 8.4%-12.4% 7 (9.7%) 8.3%-11.1% 
Infant Prophylaxis 
irrespective of 
maternal ART/ARVP 
Yes 19 (3.1%) 1.7%-4.5% 11 (2.3%) 0.9%-3.6% 30 (2.7%) 1.8%-3.7% 
 
No 43 (39.4%) 30.2%-48.7% 50 (31.1%) 23.9%-38.2% 93 (34.4%) 28.8%-40.1% 
 
Missing 4 (19.0%) 1.8%-36.3% 33 (12.6%) 8.6%-16.6% 37 (13.1%) 9.1%-17.0% 
 
Total 66 (8.8%) 6.8%-10.9% 94 (10.4%) 8.4%-12.4% 160 (9.7%) 8.3%-11.1% 
Infant ARV type 
irrespective of 
maternal ART/ARVP 
AZT+sdNVP 12 (4.8%) 2.1%-7.4% 6 (4.5%) 1.0%-8.1% 18 (4.7%) 2.6%-6.8% 
 
NVP 6 (1.9%) 0.4%-3.4% 5 (1.4%) 0.2%-2.7% 11 (1.6%) 0.7%-2.6% 
 
sdNVP 0 (0.0%) 
 
0 (0.0%) 
 
0 (0.0%) 
 
 
Unknown 0 (0.0%) 
 
0 (0.0%) 
 
0 (0.0%) 
 
 
Missing 4 (22.2%) 2.4%-42% 31 (12.4%) 8.3%-16.4% 35 (13.0%) 9.0%-17.0% 
 
Total 22 (8.8%) 6.8%-10.9% 42 (10.4%) 8.4%-12.4% 64 (9.7%) 8.3%-11.1% 
N=Total number of HIV Exposed Infants 
n = number of HIV exposed infants that tested HIV positive 
* confidence limit was amended so that the confidence intervals are bound between 0 and 100%.  
Missing: information on ARV use was not available 
 STATA did not estimate confidence intervals because point estimate was 0.0%
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4.4.7 Objective 8: MTCT risk by PMTCT protocol periods 
Two distinct protocols were in use during the 7 years under review. There was however a 
period of overlap (transitional period) between the two PMTCT protocol periods. The lowest 
MTCT risk was in period 2 (5.4%) [39/726] while the highest was in period 1 (16.4%) 
[58/353]. Details of MTCT risk are presented in Table 4.16. It took almost two and a half 
years for the two health facilities to fully transition from the 2007 to the 2010 PMTCT 
protocol. 
Table 4.16: MTCT risk by periods of PMTCT protocol at median age of 8 weeks 
(N=1651) 
PMTCT Period 
FMC Yola SH Yola Total 
n (%) 95% CI n (%) 95% CI n (%) 95% CI 
Period 1 (Jan 2008 – 
Jan 2010) 
20 (12.5%) 7.4%-17.6% 38 (19.7%) 14.1%-25.3% 58 (16.4%) 12.6%-20.3% 
Transitional Period 
(Feb 2010 – May 
2012) 
30 (9.5%) 6.3%-12.7% 33 (12.8%) 8.7%-16.9% 63 (11.0%) 8.4%-13.6% 
Period 2 (Jun 2012-
Dec 2014) 
16 (5.9%) 3.1%-8.7% 23 (5.1%) 3.0%-7.1% 39 (5.4%) 3.7%-7.0% 
Total 66 (8.8%) 6.8%-10.9% 94 (10.4%) 8.4%-12.4% 160 (9.7%) 8.3%-11.1% 
n= number of HIV exposed infants that tested HIV positive 
Period 1 PMTCT regimen: Mother: Ante partum - AZT from 28 weeks of gestation or AZT+3TC from 34-36 
weeks of gestation Intrapartum - SdNVP +AZT+3TC at onset of labour Postpartum - AZT+3TC for 7 days 
Infants: sdNVP at birth (preferably within 72 hours) plus AZT for 6 weeks. 
Period 2 PMTCT regimen: Mother:  AZT+ 3TC +EFV or NVP or LPV/r; TDF+ 3TC+ EFV from 14 weeks of 
gestation up to 1 week post cessation of breastfeeding 
Infant: NVP at birth (preferably within 72 hours) up to 6 weeks of age. 
Transitional Period: Both Period 1 and Period 2 Regimens (both regimens were in use during this period due to 
delayed transition) 
4.5 Predictors of MTCT risk 
To establish predictors of MTCT risk, simple and multiple logistic regressions analysis were 
carried out with resultant odds ratio estimated. From the simple regression analysis infant 
age, breastfeeding option, ART/ARVP receipts and year were found to be predictors of 
MTCT risk. 
All the variables listed in table 4.17 below were included in a multiple regression model. 
Infant age (>12 months), breastfeeding option (mixed fed), ART/ARVP receipts and year 
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(2012) were found to be predictors of MTCT risk. HEIs older than 12 months had 3.29 times 
(adjusted odds ratio (AOR)) the odds to be HIV positive than those ≤6 weeks while mixed 
fed infants had 2.44 times the odds to be HIV positive than infants that were not breastfed. 
The odds of the exposed infant being HIV positive was also higher (AOR = 26.37) when 
neither the mother nor the infant received prophylaxis. HEIs born in 2012 had lower odds of 
being HIV positive than those born in 2008. 
 
Table 4.17: Multivariable analysis of factors associated with MTCT risk at final end 
point using cumulative pooled data 
Variable 
 
Crude 
Odds 
Ratio 
95% CI P value 
**Adjusted 
Odds Ratio 
95% CI P value 
Gender Male 1.00 
  
1.00 
  
 
Female 1.32 0.95 - 1.83 0.096 1.16 0.71 - 1.89 0.546 
Infant Age ≤6 wks 1.00 
  
1.00 
  
 
>6 wks - 2 mons 1.12 0.53 - 2.39 0.766 0.79 0.30 - 2.11 0.636 
 
>2 mons - 6 mons *4.03 2.23 - 7.3 0.000 1.67 0.76 - 3.66 0.198 
 
>6 - 12 mons *8.67 4.75 - 15.82 0.000 1.75 0.75 - 4.05 0.194 
 
>12 mons *25.47 12.62 - 51.41 0.000 *3.29 1.24 - 8.75 0.017 
Breastfeeding 
option 
Not Breastfed 1.00 
  
1.00 
  
 
Exclusively 
Breastfed 
1.60 0.99 - 2.59 0.056 1.94 0.98 - 3.86 0.058 
 
Mixed fed *5.03 3.01 - 8.40 0.000 *2.44 1.08 - 5.52 0.032 
ART/ARV 
Prophylaxis 
Receipt 
Both Mother and 
Infant 
1.00 
  
1.00 
  
 
Mother alone *3.25 1.37 - 7.72 0.008 *2.81 1.12 - 7.04 0.028 
 
Infant alone *4.25 1.41 - 12.81 0.010 *5.64 1.79 - 17.79 0.003 
 
Neither Mother 
nor Infant 
*38.50 23.4 - 63.35 0.000 *26.37 13.96 - 49.81 0.000 
Hospital FMC Yola 1.00   1.00   
 SH Yola 1.19 0.86 – 1.66 0.293 0.47  0.005 
        
Year 2008 1.00   1.00   
 2009 1.31 0.55 – 3.10 0.544 1.23 0.27 – 5.63 0.794 
 2010 0.94 0.39 – 2.25 0.893 0.47 0.10 – 2.14 0.327 
 2011 0.61 0.25 – 1.48 0.275 0.33 0.07 – 1.52 0.154 
 2012 *0.33 0.13 – 0.85 0.022 *0.18 0.03 – 0.99 0.049 
 2013 0.40 0.15 – 1.05 0.062 0.32 0.06 – 1.63 0.169 
 2014 0.31 0.11 – 0.84 0.021 0.24 0.05 – 1.29 0.097 
*Statistically significant odds ratio           
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5.0 DISCUSSION 
This chapter discusses the results from this study in line with the study objectives and also 
compares findings with that of other published studies. It also highlights the strengths, 
limitations and challenges encountered in the course of implementing this study. 
5.1 Objective 1: Uptake of HTC 
The overall uptake of HTC was 75.9% [47,217/62,224] (95%CI: 74.3 – 77.5%) which is 
lower than the national PMTCT scale up plan target of 90%. The upper confidence interval 
limit of this estimate is close to the 77.8% obtained from the operational research conducted 
in Nigeria in 2005. Facility-level uptake of over 98% had been reported in Nigeria (Galadanci 
et al., 2013; Markson & Umoh, 2012). Since this study’s estimate only focused on women 
that attended ANC, estimated HTC uptake does necessarily reflect population level uptake. 
NDHS (2013) survey result revealed that only 20 percent of women surveyed in Nigeria were 
counselled, tested and received result during ANC.  
There were some improvement in HTC uptake at the study sites over the years when 
compared with the 2008 baseline; the student thinks this could have been as a result of 
improvement in service delivery and programme acceptance by the end users. Going by the 
documentation in the HTC register and feedback from the health facility staff, a number of 
reasons accounted for women not getting tested. These include non-availability of HIV test 
kits and some mothers requesting to get their husband’s consent before they can get tested. It 
should however be noted that this estimate does not include women with known HIV status at 
the time of ANC attendance who are typically not re-tested during ANC. 
5.2 Objective 2: Maternal/Antenatal HIV positivity rate 
The overall maternal HIV positivity rate at the two study sites was 3.1% [1,475/47,217] 
(95%CI. 3.0% - 3.3%). Expectedly in terms of absolute numbers, there were more HIV 
http://etd.uwc.ac.za
59 
 
positive pregnant women for SH Yola than FMC Yola. There was however overlap in CIs for 
the overall maternal HIV positivity rates for the two health facilities. There was a general 
decline in maternal HIV positivity rate from 2008 to 2014 (5.5% [297/5,365] to 1.5% 
[117/7,636]) though there was a slight rise in 2012 (2.6% [145/5541] in 2011 to 3.4% 
[224/6,603] in 2012). A number of reasons could have contributed to this general decline one 
of which is the intensified effort towards prevention of HIV which translated to decline in 
new infections. The rise in maternal HIV positivity rate from 2011 to 2012 could have been a 
result of reduction in the number of people dying from HIV or recline to risky sexual 
behavior by the time people realized that HIV infection can be managed (Bashorun et al., 
2014). Similar increase in national prevalence was observed between 2005 and 2008 (from 
4.4% to 4.6%) in Nigeria. With the decentralization of ART services to primary health 
centres (PHCs) between 2012 and 2014, the student posits that it is likely that other HIV 
positive women that would have otherwise attended the 2 study sites received HTC services 
and were diagnosed at these PHCs. Again women with previously known HIV estimate were 
not included in this estimate since they are not typically re-tested during ANC. 
 
The cumulative estimate from this study is lower than the maternal HIV positivity rates of 
3.7%, 5.5%, 12.7% and 15.1% that have been reported in some studies conducted in Nigeria 
using data from 2009 and 2011 (Chama et al., 2010; Galadanci et al., 2013; Okafor et al., 
2014; Markson & Umoh, 2012).  
The HIV positivity rate of 5.5% [297/5,365] (95% CI: 4.8%- 6.2%) for 2008 is lower than the 
national average of 4.6% (estimate falls within 95% CI) as well as the state specific estimate 
of 6.8% (FMoH, 2010b).   
For 2010, the national HIV prevalence was 4.1% while the state specific prevalence was 
3.8% (2.6% - 5.1%), Yola-the town in which the 2 study sites are located had a prevalence of 
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2.7% (0.8% - 4.5%), the estimate of 3.5% [214/6,138] from this study falls within the 
confidence interval for both the state and Yola town (FMoH, 2010b). The National  
HIV/AIDS  and  Reproductive  Health  Survey  (NARHS)  conducted  in  2012 estimated the 
national HIV prevalence to be 3.4% (NACA, 2014b), this value is the same as the 2012 
estimate for this study. From the 2014 sentinel survey, the HIV prevalence for Nigeria and 
Adamawa State were 3.0%, 2.5% respectively while the urban areas in Adamawa state had a 
prevalence of 2.2% (1.3% - 3.7%) (FMoH, 2014b). The point estimate of 1.5% [117/7,636] 
for 2014 also falls with the confidence interval for urban areas in Adamawa State. 
Except for the slight rise in maternal HIV positivity rate in 2012, findings from this study is 
similar to the results of the HIV seroprevalence sentinel survey which showed a consistent 
decline in prevalence from 2010 to 2014 (FMoH, 2014b). This finding suggests that the 
investment in HIV prevention, care and treatment is yielding positive results.  
5.3 Objective 3: Uptake of ART/ARVP 
Based on available records, the overall uptake of ART/ARVP was 85.7% [192/224] (95% CI 
81.1% - 90.3%). Prophylactic records were however only available for 15.2 percent of 
women that tested HIV positive (other records are either missing or could not be 
longitudinally linked) hence the uptake of ART/ARVP may not be representative of true 
situation in the two health facilities and it is likely to be an overestimate. Most (84.8%) of the 
folders for HIV positive pregnant women could not be located either because the women did 
not receive antiretroviral interventions or because of poor record keeping practice. Review of 
routine data on ART/ARVP uptake from April 2011 to 2014 gave an overall ART/ARVP 
uptake of 57.7% (95% CI 44.6-70.7%). This data was however not limited to ANC attendees 
but also include pregnant women diagnosed during labour and delivery and those referred 
from other health facilities. UNAIDS’s (2016b) statistics revealed that population level 
ART/ARVP uptake is much lower than the 2 estimates stated above as only 30% of pregnant 
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women living with HIV are accessing ARVs to prevent MTCT. Several factors could have 
contributed to non-receipt of ART/ARVP by HIV positive pregnant women. This includes 
poor referral, lack of ARVs at the time of diagnosis, poor counselling due to inadequate time 
(occasioned by high workload due to inadequate manpower) and refusal of HIV positive 
pregnant women to receive ART/ARVP due to cultural belief (this is closely linked with low 
level of education (Rogers-Bloc & Quail, 2002; Chama, Audu & Kyari, 2004; Ndikom & 
Onibokun, 2007; Peltzer et al., 2008; Oladokun et al, 2010; Mirkuzie et al., 2011; Nkwo, 
2012; Chabikuli et al., 2013; NACA, 2013). In order to tackle the scourge of MTCT; 
strategies must involve measures that will improve women’s attendance at ANC and 
subsequent uptake of HTC and ART/ARVP as well as delivery at health facilities which will 
increase the likelihood of the infant receiving ARVP (Galadanci et al., Undated). 
5.3.1 Predictors of ART/ARVP uptake 
Women that were between 25-34 years were found to be approximately three times (3.04) 
more likely to receive ART/ARVP than those aged 15-24 years. The student thinks this is 
likely due to the fact that the former are more matured and appreciate the need to protect the 
HEI better. 
5.4 Objectives 4-8: MTCT risk in general and turnaround time for DNA PCR 
test results, MTCT risk by age, by feeding option, by ARV use and by 
PMTCT protocol period 
5.4.1 Objective 4: Overall MTCT risk and turnaround time for DNA PCR test 
results 
The overall MTCT risk for this study was 9.7% [160/1651] (95% CI 8.3% - 11.1%) at 
median age of 8 weeks (IQR= 6-20). This is very close to the MTCT risk of 9.8% reported by 
Inalegwu et al. (2016) and not too far from the MTCT risk of 11.0% reported by Aliyu et al. 
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(2014) and 13.0% at 6 weeks projected for Nigeria by UNAIDS (UNAIDS, 2016b). Ayouba 
et al. (2003) also reported an overall MTCT risk of <13% in Cameroun. Studies done in other 
African countries had reported overall MTCT risks that ranged from 8.8 % - 15.7% (Coetzee 
et al., 2005; Azcoaga-Lorenzo et al., 2011; Ngemu et al., 2014). 
 
The median turnaround time of 48 days (IQR: 31-78) is almost two times the recommended 
28 days. This value is close to the 47 days (IQR: 35-58) reported by Anoje et al. (2012) in 
their study at selected health facilities in two states in South-South Nigeria and higher than 
the TAT of 25 days reported in a study conducted in Lagos, Nigeria (Audu et al., 2014). The 
health facility staff reported that the very high TAT of >100 days for 2013 and 2014 could 
have been as a result of lack of reagents or equipment breakdown at the central testing 
laboratory. High TAT could pose additional financial burden on caregivers as they may have 
to visit the health facility more than once to get the DNA PCR result of their infants. With 
this high TAT, they also have to wait anxiously for a longer time to know their infant’s 
status. Additionally non-timeliness of result can result in delayed initiation of HIV positive 
infant on ART (Anoje et al., 2012). 
5.4.2 Objective 5: MTCT risk by age 
With MTCT risk of 3.0% [15/499] - 3.4% [13/387] among infants aged 2 months and below, 
11.1% [49/441] among those that are >2 months - 6 months and  21.1% [51/242] -34.9% 
[30/86] among those that are older than 6 months, MTCT risk increased with age. This trend 
is similar to the findings reported by Anoje et al. (2012) and Kalu et al. (2014) in their 
studies. This increased risk could have been as a result of prolonged breastfeeding, given that 
most infants (70.7%) were either exclusively breastfed or mixed fed. Prolonged breastfeeding 
has been proven to increase risk of MTCT (Newell, 2001; The Breastfeeding and HIV 
International Transmission Study Group et al., 2004). This is partly due to the fact that a 
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higher proportion of the mother-infant pair in the older age bracket did not receive 
prophylaxis (37% for HEIs > 12months versus 2-7% for HEIs that were 2 months or less). 
When infants are breastfed, around 39% of MTCT can occur during this period (Kourtis et 
al., 2006). 
5.4.3 Objective 6: MTCT risk by breastfeeding option 
It has been established that one of the means through which MTCT occurs is through 
breastfeeding (WHO, 2010a). This discovery had informed the decision of developed 
countries to adopt the policy of replacement feeding for all HEIs (Darak et al., 2014). From 
the result of this study, infants that were not breastfed had the least MTCT risk (5.4%) 
[39/726] irrespective of prophylaxis use.  With the challenge of meeting the AFASS criteria 
in developing countries, exclusive breastfeeding is recommended even though it carries a 
higher risk as this study has validated (8.3%) (Federal Ministry of Health, 2007; Federal 
Ministry of Health Nigeria, 2010a; Federal Ministry of Health, 2014a). Mixed fed infants had 
significantly higher risk (22.4%) [58/259] of MTCT than the babies fed using the other two 
breastfeeding options. Mixed feeding is known to predispose infants to HIV especially in 
early life as formula feeds can erode intestinal linings resulting in HIV infection (Wise, 
2001). 
The study conducted by Kalu et al. (2014) also showed similar MTCT risk pattern. 
5.4.4 Objective 7: MTCT risk by receipt of ART/ARVP  
Efficacy studies have proven that antiretroviral interventions can reduce MTCT risk 
(Chaisilwattana et al., 2002; Connor et al., 1994; Dabis et al., 2005).  Similar evidence is also 
available for effectiveness studies in a number of settings (De Cock et al., 2000; Kumar et al., 
1995; Lallemant et al., 1994; WHO, 2010a). The result of this study further buttressed the 
effectiveness of PMTCT especially when mother and infant receive intervention irrespective 
of breastfeeding option. The low MTCT risk of 2.4% [25/1,034](95%CI: 1.5%-3.4%) among 
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this category of mother-infant pair suggests that virtual elimination of MTCT is feasible in 
resource limited settings. The finding that MTCT risk is lower when mothers alone receive 
ART/ARVP compared to when infants alone did is consistent with the findings of some other 
studies in Nigeria (Anoje et al., 2012; Chukwuemeka et al., 2014). 
 
The fact that not all mother-infant pairs are receiving prophylaxis despite the availability of 
these services at the health facilities (also seen in some other studies (Coetzee et al., 2005; 
Torpey et al., 2012)) calls for the need to put measures in place to ensure that pregnant 
women access antiretroviral interventions. The triple ARV regimen appears to be the most 
effective ARV regimen as none of the babies whose mothers received triple regimen for 
ARVP tested positive. In comparison with the meta-analysis conducted by Adane (2012) 
using PMTCT studies from Sub Saharan Africa countries, the MTCT rate of 9.1% [2/22] for 
mothers that received sdNVP is lower than the point estimate of 9.7% from Adane’s (2012) 
study even though the 9.1% falls within the quoted 95% CI of 7.8 – 12.0%, the MTCT rate 
for the AZT +sdNVP and triple regimen groups were also lower than the risk obtained from 
the Adane’s study (2.9% [1/35] Vs 7.1%  (95% CI 6.0% -8.4%) and 0.0% [0/116] Vs 4.0% 
(95% CI: 2.7% - 6.1%) respectively). Unlike Kesho Bora’s study that quoted similar 
effectiveness for AZT+sdNVP and triple regimen (AZT + sdNVP:  5·0% 95% CI 3·3-7·7%; 
triple regimen: 3·3% 95% CI: 1·9-5·6%), the fact that none of the HIV exposed babies in the 
latter group for this study was HIV positive suggests that triple regimen may be more 
effective. 
5.4.5 Objective 8: MTCT risk by PMTCT protocol periods 
The lowest PMTCT risk was observed during the period when triple regimen was in use for 
ARVP. This further buttressed the need for countries to adopt either Option B or Option B
+
 
as the preferred PMTCT regimen. With the recent adoption of Option B+ by Nigeria 
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(UNAIDS, 2016b), Nigeria stands the chance of achieving virtual elimination if coverage of 
services can be improved.  
The two and a half transitional period from the 2007 to the 2010 PMTCT guideline is 
however long and showed that prescribing habit may not change immediately after the 
introduction of a new guideline hence the need for intensified engagement to ensure prompt 
migration. 
5.5 Predictors of MTCT risk 
The predictors of MTCT risk (infant age, breastfeeding option, ART/ARVP receipt and year 
(closely linked with PMTCT protocol in use) identified in this study have been well 
documented in literature as factors associated with MTCT risk (Newell, 2001; Ikechebelu et 
al., 2011; Azcoaga-Lorenzo et al., 2011; Afe et al., 2011; Anoje et al., 2012; Chukwuemeka 
et al., 2014; Kalu et al., 2014). 
Feeding option influences MTCT risk and the risk increases with breastfeeding duration. 
Prolonged breastfeeding can double MTCT risk (Newell, 2001; The Breastfeeding and HIV 
International Transmission Study Group et al., 2004). The 2016 WHO guidelines 
recommended that is settings where breastfeeding improves child survival; exclusive 
breastfeeding is recommended for the first six months of life after which complementary 
foods can be introduced with breastfeeding continued for up to 1 year (WHO, 2016). Use of 
ART/ARVP has also been found to substantially protect against MTCT (De Cock et al., 
2000; Kumar, Uduman, & Khurranna, 1995; Lallemant et al., 1994; WHO, 2010a).  
5.6 Strengths, challenges and limitations of this study 
5.6.1 Strengths of this study 
This study analyzed data gathered from two health facilities over a 7-year period hence it 
provided evidence for more than one site over an extended period of time. Most of the 
facility-based PMTCT effectiveness studies in Nigeria were single-site studies conducted at 
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tertiary or teaching hospitals. This study however included a secondary health facility as one 
of the two study health facilities thus providing additional evidence on PMTCT effectiveness 
in a secondary health facility which may not have as much specialized health personnel as 
tertiary or teaching hospitals. Most of the published Nigerian studies also reported findings 
during one period of the PMTCT protocol; this study however compared MTCT risks during 
2 periods of PMTCT policy changes in Nigeria as well as during the transitional period. The 
sample sizes for this study were also larger than most of the other Nigerian studies. 
5.6.2 Challenges encountered in the course of this study 
The major challenge encountered in the course of implementation of this study is the poor 
documentation and record keeping practices at the two health facilities. This made data 
retrieval difficult and time consuming and also made linking of mother-infant pair record 
difficult. The pool of data that was included in the final analysis was also reduced due to 
missing records. 
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5.6.3 Limitations of this study 
 
This study is biased towards pregnant women that attended ANC and HEIs that were brought 
by their caregivers for HIV DNA PCR testing and for which results were available. As the 
study only focused on pregnant women that attended ANC, exclusion of non-attendees may 
lead to overestimation of uptake of HTC/ART/ARVP. Women that did not attend ANC 
would likely not have accepted HTC or ART/ARVP. ) With missing record on ARV use for 
84.8% (1,251) of HIV positive pregnant women, uptake of ART/ARVP may not be 
representative of true situation in the two health facilities and it is likely to be an 
overestimate. Similarly only HEIs that were brought back for HIV DNA PCR testing were 
studied, the exclusion of HEIs that may be HIV positive but not brought for testing by 
caregivers would result in underestimation of MTCT risk. Due to the poor tracking 
mechanism at the health facilities and non-documentation of some mother’s hospital number 
in the EID/Child follow up register, it is difficult to link mother-infant pair record for 
information on mode of delivery, mother’s CD4+ cell count, duration of ART/ARVP use, 
adherence to ART/ARVP and so on. This study therefore did not assess the effect of these 
variables on MTCT risk. The data for this study were mostly analyzed cross-sectionally 
therefore the numerators and denominators at each step of the PMTCT cascade do not 
necessarily refer to the same groups of women. The only exception to this was in the 
establishment of uptake of ART/ARVP where it was individually established if HIV positive 
women received ART/ARVP. Mother-infant pair record was not longitudinally tracked and 
the HEIs were not necessarily delivered by the pregnant women that tested positive during 
ANC. Information on mother and infant’s ARV use and breastfeeding option were however 
available in either or both the EID follow up register and PCR request and result form. 
Finally given that second HIV DNA PCR test result was only available for 2.7% (35) of 
HEIs, our estimates largely assessed MTCT risk at the time of first testing and not at the final 
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end point (post ceasation of breastfeeding). Reasons that could account for few babies getting 
final EID test include: poor PMTCT counselling, lack of money for transportation due to 
poor economic status, shortage of DBS test kits among others (NACA, 2013; Chabikuli et al., 
2013). Routine data review may therefore not be the best approach for assessing effectiveness 
of PMTCT when the interest is to establish the final HIV status of HEIs post ceasation of 
breastfeeding.         .
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6.0 CONCLUSION AND RECOMMENDATIONS  
This chapter summarizes findings from this study and also provides key recommendations 
that can help improve PMTCT services and assess progress towards virtual elimination. 
6.1 Conclusion 
This study has demonstrated that PMTCT-related services are being accessed by pregnant 
women even though the uptake of HTC and ART/ARVP among pregnant women that visited 
the two health facilities were below the national PMTCT scale up plan’s (2010-2015) target 
of 90 percent. The MTCT risk estimates also proved that PMTCT interventions are effective 
especially when both mother and infant received ARV interventions. Option B appears to be 
the most effective regimen against MTCT, compared with older regimens, and should be 
strongly encouraged. The high MTCT risk among infants that were mixed fed suggests that 
this mode of breastfeeding should be discouraged from a transmission perspective in the 
context of PMTCT Option A (not Option B+ with viral load suppression). With the high 
turnaround time of 49 days observed for this study, the logistics of DBS sample 
transportation need to be strengthened. Given the expansion of treatment sites and by 
extension service coverage since the last country-level evaluation, it is important that Nigeria 
carries out another evaluation of her program as was done in countries like South Africa. This 
will help in assessing progress towards Nigeria’s PMTCT targets (Federal Ministry of Health 
Nigeria, 2010a). 
6.2 Recommendations 
6.2.1 Recommendations at health facility and implementing partner level  
 For ease of data retrieval and review, the administrations of the two health facilities 
need to improve on their record filing and retrieval system. In addition there is a need 
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to put in place strategies for improving the quality of data and entrenching validation 
processes as a reasonable number of records and variables were missing. 
 There is a need to strengthen the referral system between the ANC, patient monitoring 
and management (PMM) and pharmacy units in order to ensure that all diagnosed 
HIV positive women receive prophylaxis. 
 The management of the two health facilities as well as the implementing partner also 
needs to improve the contract tracking system for pregnant women in order to ensure 
that they bring their infants on time for EID testing in accordance with the national 
testing algorithm. 
 More effort is required to ensure timely transition during periods of PMTCT protocol 
changes. 
 The logistics of DBS sample transportation needs to be strengthened in order to 
ensure that mothers have timely access to the DNA PCR result of their infant which in 
turn will ensure early initiation of HIV positive infant.  
6.2.2 Recommendation at policy level  
 The country should ensure that Option B or Option B+ is in use in all health facilities 
offering PMTCT services in the country as this is highly effective against MTCT. 
 The Government should also ensure that optimal number of health workers is 
available for service delivery in addition to guarantying continuous supply of HIV 
commodities. 
6.2.3 Other recommendations 
 Further research is required to: 
o identify strategies for increasing utilization of PMTCT services by women that 
are not currently accessing services at health facilities 
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o assess cost effectiveness of Option B+ and strategies for improving adherence 
among women that do not require ARV for their own health. 
o assess country-wide PMTCT effectiveness as none of the studies in Nigeria is 
nationally representative. 
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Appendix 1: Flow chart showing cascade of events involved in PMTCT interventions 
(2008 – 2014) 
 
 
 
 
                                     
 
 
                                                                                                                                     Option 1  
 
 
 
  
                                                                                                                               
                
                                                                                                                                   Option 2 
 
 
 
 
                                                                                                                       
 
 
 
 
 
 
 
 
 
 
 
 
Pregnant woman 
attends ANC 
Test for HIV 
Breastfeed 
exclusively for 
the first 6 months 
complementary 
feeds can be 
introduced 
thereafter and 
either stop or 
continue 
breastfeeding for 
up to 1 year 
Re-test in 3 
months’ time 
HIV negative 
 
Counsel 
on infant 
feeding 
option 
HIV positive 
Use 
replacement 
feeding 
(commercial 
infant 
formula) 
*Assess for ART 
eligibility 
Eligible Ineligible 
Provide adherence counseling and 
*Commence ART 
*Commence Maternal ARV prophylaxis 
Test for HIV at 6 weeks using 
DNA PCR. ≥9 months do 
HIV rapid test before PCR 
Delivers HIV Exposed Infant 
Give Infant ARV 
Prophylaxis and Co-
trimoxazole from 6 
weeks  
HIV positive 
 
Commence ART 
HIV negative 
Re-test for HIV at 
6 weeks post 
weaning 
If HIV          
positive If Negative, 
Confirmed 
Negative 
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ANC, Antenatal clinic; ART, Antiretroviral Therapy; ARV, Antiretroviral drugs; DNA PCR, Deoxyribonucleic 
Acid Polymerase Chain Reaction; See Appendix 2 for Nigeria’s eligibility criteria and recommended ARVs  
between 2007 and 2014 (Federal Ministry of Health, 2007; Federal Ministry of Health Nigeria, 2010a ; Federal 
Ministry of Health, 2014a) 
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Appendix 2: ART and PMTCT eligibility criteria and regimens 
 
2007 National 
Guidelines 2010 National Guidelines 
2014 National 
Guidelines 
 
PMTCT Eligibility Criteria/PMTCT Regimens  
Mother 
WHO Clinical Stage I, II 
with CD4+ cell count 
>200 cells/mm
3
; WHO 
Clinical Stage III with 
CD4
+
 cell count >350 
cells/mm
3
 
Ante partum 
Give AZT from 28 weeks 
of gestation or AZT+3TC 
from 34-36 weeks of 
gestation 
Intrapartum 
 SdNVP +AZT+3TC at 
onset of labour 
Postpartum  
AZT+3TC for 7 days 
 
Health Facility CAN 
monitor triple ARV 
(Option B) 
Health Facility 
CANNOT monitor 
triple ARV (Option A) 
WHO Clinical 
Stage I or II with 
CD4
+
 cell count 
>500 cells/mm
3
  
 
 
 
Give 
TDF/3TC/EFV at 
the time of 
diagnosis up to 1 
week post 
cessation of 
breastfeeding 
WHO Clinical Stage I 
or II with CD4
+
 cell 
count >350 cells/mm
3,  
 
Give AZT+ 3TC 
+EFV or NVP or  
LPV/r; 
TDF+ 3TC+ EFV from 
14 weeks of gestation 
up to 1 week post 
cessation of 
breastfeeding 
WHO Clinical Stage I 
or II with CD4
+
 cell 
count >350 cells/mm
3
  
 
Give AZT from 14 
weeks of gestation, 
sdNVP at onset of 
labour and delivery, 
AZT+3TC 12hourly 
during labour and 
delivery and 12 hourly 
for 7 days post-partum 
*Infant 
sdNVP at birth 
(preferably within 72 
hours) plus AZT for 6 
weeks. 
NVP at birth 
(preferably within 72 
hours) up to 6 weeks 
of age. 
Not Breastfeeding 
NVP at birth 
(preferably within 72 
hours) up to 6 weeks of 
age 
Breast feeding 
NVP at birth 
(preferably within 72 
hours) up to 1 week 
post cessation of 
breastfeeding  
NVP at birth 
(preferably within 
72 hours) up to 6 
weeks of age. 
  
ART Eligibility Criteria/ART Regimens 
Mother 
WHO Clinical Stage IV 
irrespective of CD4
+
 cell 
count 
WHO Clinical Stage III if 
CD4
+
 cell count < 350 
cells/mm
3
 
WHO Clinical Stage I and 
II if CD4
+ cell count is ≤ 
200 cells/mm
3 
 
Give AZT+ 3TC +EFV or 
NVP or  LPV/r 
 
WHO clinical stages 
III or IV irrespective of  
CD4
+
 cell count and 
CD4+ cell count ≤350 
cells/mm
3 
irrespective 
of WHO clinical 
staging 
 
 
 
 
 
 
Give 
AZT+3TC+LPV/r or 
EFV or ABC;  
 
 
WHO clinical stages III 
or IV irrespective of 
CD4
+
 cell count and 
CD4+ cell count ≤350 
cells/mm3 irrespective 
of WHO clinical 
staging 
 
 
 
Give AZT+3TC+LPV/r 
or EFV or ABC; 
TDF+3TC or FTC + 
EFV 
WHO clinical 
stages III or IV 
irrespective of 
CD4+ cell count 
and CD4+ cell 
count ≤500 
cells/mm3 
irrespective of 
WHO clinical 
staging 
 
 
 
 
Give 
TDF/3TC/EFV 
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2007 National 
Guidelines 2010 National Guidelines 
2014 National 
Guidelines 
TDF+3TC or FTC + 
EFV 
Infant 
WHO pediatric HIV 
Clinical Stage III or IV 
irrespective of CD4
+
% 
 WHO pediatric HIV 
Clinical Stage II if 
CD4
+
% < 20%  
Give AZT+3TC+NVP or 
EFV. ABC+3TC+NVP or 
EFV d4T+3TC+NVP or 
EFV 
 
All infants ≤ 2 years 
  
 
 
 
Give AZT+3TC+NVP 
or LPV/r or ABC or 
EFV. ABC+3TC+NVP 
or LPV/r  
d4T+3TC+NVP or 
LPV/r 
 
All infants ≤ 2 years  
 
 
 
 
Give AZT+3TC+NVP 
or LPV/r or ABC or 
EFV. ABC+3TC+NVP 
or LPV/r 
d4T+3TC+NVP or 
LPV/r 
All infants ≤5 
years  
 
 
Give 
AZT+3TC+NVP 
or LPV/r or ABC 
or EFV 
3TC, Lamivudine; ABC, Abacavir; ARV, Antiretroviral drug; AZT,  Zidovudine;  CTX, Co-
trimoxazole; FTC, Emtricitabine;  LPV/r, Lopinavir/ritonavir; NVP, Nevirapine; sdNVP, 
single dose; Stavudine, d4T; Tenofovir, TDF; WHO, World Health Organization.         
*Initiate CTX at 6 weeks and continue until infant is confirmed to be HIV negative-post 
cessation of breastfeeding 
NB: SH Yola and FMC Yola implemented 2007 National guidelines between 2007 and 
January 2010 while Option B of 2010 National Guidelines was implemented between 
February 2010 and December 2014. 
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Appendix 3: 2010-2015 National PMTCT scale up targets 
 To provide access to at least 90% of all pregnant women to quality HIV counselling 
and testing by 2015 
 To provide access to at least 90% of all HIV positive pregnant women to more 
efficacious ARV prophylaxis by 2015  
 To provide access to at least 90% of HIV exposed infants to more efficacious ARV 
prophylaxis by 2015 
  To provide access to at least 90% of HIV positive pregnant women to quality infant 
feeding counselling by 2015 
  To provide access to at least 90% of all HIV exposed infants to early infant diagnosis 
services by 2015.  
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Appendix 4: Summary of findings from PMTCT efficacy studies 
Author Study Name Location Prophylaxis MTCT risk 
Connor et 
al., 1994 
*PACTG076/
ANRS 024 
United 
States of 
America 
and France 
Mother                                                        
AZT from 14 weeks of 
gestation till birth                       
Infant                                                                 
AZT for 6 weeks 
(formula fed) 
8.3% at 18 
months-infant 
pair received 
prophylaxis as 
opposed to 
25.5% in the 
placebo group 
     
Chaisilwatta
na et al., 
2002 
Thai ZDV + 
3TC trial 
Thailand 
Mother                                                                   
AZT and 3TC from 34 
weeks of gestation 
Infants                                                             
AZT for 4 weeks 
(formula fed) 
2.8% at 18 
months
     
Dabis et al., 
2005 
DITRAME/Plu
s ANRS 
1201.1 trial 
Abidjan, 
Cote 
d’Ivoure 
Mother                                                                 
AZT, 3TC and sdNVP 
from 32 weeks of 
gestation up to 3 days 
post-delivery 
4.7% at six 
weeks 
AZT and sdNVP from 
36 weeks of gestation up 
to three days post-
delivery 
6.5% at six 
weeks 
Short course AZT for 36 
to 38 weeks. 
All exposed infants in 
the study group received 
sdNVP and 1 week 
course of AZT and were 
either formula fed or 
exclusively  breastfed 
12.5% at six 
weeks 
 
 
    
* Ground breaking clinical trial that paved way for the use of ARVs for PMTCT 
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Appendix 5: Summary of findings from selected facility-level PMTCT effectiveness studies 
Authors 
name 
Study 
Period 
Study Site Methodology 
Sample 
Size 
PMTCT/ART Regimen 
MTCT Risk 
Age of 
Testing Mother Infant 
FACILITY-LEVEL STUDIES FROM COUNTRIES OTHER THAN NIGERIA 
Ayouba et 
al., 2003 
Jan 
2000-
Dec 
2002 
Three HFs in 
Yaoundé 
Cameroun 
Prospective 
Cohort Study 
123 HIV 
exposed 
infants 
sdNVP at onset of 
labour 
sdNVP 
within 72 
hours of 
life 
+
Overall <13% 
6 wks 
Infants 
with high 
viral load 
10.6%  (95% 
CI, 5.1-16.0) 
          
Coetzee et 
al., 2005 
Mar –
Nov 
2003 
Three Clinics 
in 
Khayelitsha, 
South Africa 
Cross 
sectional 
study 
658 
mother-
infant 
pairs 
Prior to July 2003 
AZT from 34 
weeks of gestation 
(AZT-based 
protocol) 
 
July 2003 onwards 
Mothers that had < 
2 weeks of AZT 
also received 
sdNVP at onset of 
labour (NVP-based 
protocol) 
NVP 
within 72 
hours 
Overall 8.8% (6.2-10.9) 
Median 
age of 6.6 
wks (IQR, 
6.1–10.1) 
AZT-based 
protocol 
8.8% (5.5-13.1) 
NVP-based 
protocol 
7.5% ( 3.1-14.9) 
Either 
AZT-based 
protocol or 
NVP-based 
protocol 
8.4% ( 5.7-11.9) 
          
Azcoaga-
Lorenzo et 
al., 2011 
Jan 
2006-
Dec 
2008 
Western rural 
Kenya (Busia 
Kenya) 
3dispensaries 
5 health 
centres 
2 sub-district 
hospital      
Case-control 
study 
22,566 
Tested 
Pregnant 
Women 
767 HIV 
Exposed 
Infants 
AZT for 4 weeks, 
sdNVP and AZT + 
3TC 
 
OR 
ART 
SdNVP 
and AZT 
for 7 days 
Overall 
(after 
breastfeedi
ng) 
15.68%  (11.6-
20.1) 
6 wks post 
weaning 
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Authors 
name 
Study 
Period 
Study Site Methodology 
Sample 
Size 
PMTCT/ART Regimen 
MTCT Risk 
Age of 
Testing Mother Infant 
1mission 
hospital 
          
Torpey et 
al., 2012 
Sep 
2007 – 
July 
2010 
Five 
Zambian 
Provinces 
Analysis of 
PCR results 
28,320 
HIV 
Exposed 
Infants 
Period 1 (Sep 2007 
– Jan 2009) 
 
SdNVP 
 
Period 2 (Feb 2009 
– Jul 2010) 
 
AZT + sdNVP 
sdNVP 
Overall 12.20% 
6 weeks 
Period 1 15.10% 
Period 2 11.0% 
MP + IP 
5.8% (5.1% – 
6.5%) 
MP only 
10.5% (7.7% - 
13.4%) 
IP only 
15.8% (6.9% – 
24.5%) 
No 
interventio
n 
21.8% (16.8% - 
26.9%) 
ART 
4.2% (3.3% - 
5.1%) 
AZT+ sd 
NVP 
6.8% (5.8% - 
7.9%) 
sdNVP 
8.7% (7.1% - 
10.4%) 
No 
interventio
n 
20.1% (15.8% - 
24.3%) 
          
Ngemu et 
al., 2014 
Nov 
2009 – 
Jan 
2011 
Daughters of 
Charity of St. 
Vincent De 
Paul 
DREAM 
Cross 
Sectional 
50 HIV 
positive 
pregnant 
women 
and their 
AZT + 3TC +NVP NVP Overall 10.0%  
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Authors 
name 
Study 
Period 
Study Site Methodology 
Sample 
Size 
PMTCT/ART Regimen 
MTCT Risk 
Age of 
Testing Mother Infant 
Centre in 
Nairobi, 
Kenya 
exposed 
infants 
          
Moodley et 
al., 2013 
Oct 
2004 – 
Dec 
2012 
KwaZulu –
Natal, South 
Africa 
Analysis of 
PCR results 
369,615 
HIV 
Exposed 
Infants 
 
Period 1 
Sd NVP in labour 
and within 72 hours 
of delivery 
 
Period 2 
AZT from 14 wks, 
sdNVP in labour 
and stat dose of 
TDF +FTC post 
delivery 
Period 1 
sdNVP 
within 72 
hours of 
delivery 
 
Period  2 
6 wks of 
NVP (if 
not 
breastfed), 
If 
breastfed 
continue 
for 
duration 
of 
breastfeed
ing 
sdNVP 
27.5% (19.1 – 
36.2%) 
4 -8 wks 
Triple 
regimen 
2.9% (2.8 – 
3.0%) 
          
*Sagna et 
al., 2015 
Oct 
2009 – 
Jun 
2013 
Saint Camille 
Medical 
Centre 
Ouagadougo
u Burkina 
Cohort 
3,215 
pregnant 
women 
with less 
than 32 
Prophylaxis 
AZT from 28 
weeks, AZT + 3TC 
+ NVP during 
labour, AZT/3TC  
 
Overall 0.52% 
6 months 
 
MP 1.75% 
MP + RF 1.09% 
MP + BF 4.55% 
ART+RF 0.00% 
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Authors 
name 
Study 
Period 
Study Site Methodology 
Sample 
Size 
PMTCT/ART Regimen 
MTCT Risk 
Age of 
Testing Mother Infant 
Faso weeks of 
amenorr
hea 
394 HIV 
positive 
pregnant 
women 
388 HIV 
Exposed 
Infants 
first week post-
partum 
 
ART 
AZT+3TC or d4T 
+3TC + NVP or 
LPV/r or IDV/r 
NIGERIA'S FACILITY-LEVEL STUDIES 
Agboghoro
ma, Audu 
and Iregbu, 
2015 
Jan 
2006 – 
Dec 
2008 
National 
Hospital, 
Abuja 
Retrospective 
Cohort Study 
643 
pregnant 
women 
247 HIV 
Exposed 
Infants 
Prophylaxis 
Sd‑NVP in labor 
AZT + 3TC  for 7 
days postpartum 
ART 
AZT+3TC+NVP or 
LPV/r or IDV/r or 
SQV/r 
 
sdNVP + 
AZT for 6 
weeks 
Overall 2.4% 
6 weeks 
Triple 
Regimen 
1.3% 
Intrapartum 
NVP 
37.5% 
ECSD 1.6% 
Vaginal 
Delivery 
5.5% 
EBF 12.5% 
MF 
++
0.0% 
RF 2.1% 
          
Chama, 
Gashau, & 
Oguche, 
2007 
2007 
University of 
Maiduguri 
Teaching 
Hospital, 
Nigeria 
Cohort Study 
5,461 
tested 
pregnant 
women 
 
695 
HIV-
Prophylaxis 
sdNVP in labour 
ART 
d4T+3TC+NVP 
sdNVP 
within 72 
hours of 
delivery 
sdNVP 33.3% 
 
ART 9.1% 
ART+ECS
D+RF 
0.0% 
       
**Chama et 
al., 2010 
2010 ART 
sdNVP 
within 72 
Overall 1.1% ≥6 months 
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Authors 
name 
Study 
Period 
Study Site Methodology 
Sample 
Size 
PMTCT/ART Regimen 
MTCT Risk 
Age of 
Testing Mother Infant 
positive 
pregnant 
women 
446 
mother-
infant  
pairs 
hours of 
delivery 
and AZT 
for 6 
weeks 
          
Afe et al., 
2011 
Feb 
2007 - 
Feb 
2008 
6 HFs in 
Lagos 
Nigeria 
A review of 
DNA PCR 
result of HEIs 
733 HIV 
exposed 
infants 
  
Overall 22.5% 
 
MP or 
mART 
only 
9.6% 
          
Audu et 
al.,2014 
Feb 
2007 - 
Oct 
2008 
6 Health 
Facilities in 
Lagos State 
Analysis of 
EID Data 
1,273 
HIV 
Exposed 
Infants 
  
Overall 22.0% 
12.6 wks 
(1 day - 
71.6 wks) 
Range 
across 
health 
facilities 
7.1%-38.4% 
At age 48-
72 wks 
41.1% 
          
Anoje et al., 
2012 
Nov 
2007 - 
Jul 2009 
6 HF in 
Cross River 
and Akwa 
Ibom States 
Nigeria 
Review of  
Early Infant 
Diagnosis 
(EID) records 
702 HIV 
Exposed 
Infants 
Prophylaxis 
AZT from 28 
weeks OR AZT + 
3TC from 33 weeks 
sd NVP in labour 
ART 
AZT or d4T + 3TC 
+ NVP or EFV 
sd NVP 
within 72 
hours and 
AZT for 6 
weeks 
MP or 
mART + 
IP 
4.8% (1.3- 8.3) 
13 weeks 
IQR 6.5 - 
30.5 
No 
interventio
n 
19.5% (3.0- 
35.5) 
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Authors 
name 
Study 
Period 
Study Site Methodology 
Sample 
Size 
PMTCT/ART Regimen 
MTCT Risk 
Age of 
Testing Mother Infant 
Esene & 
Omoigberal
e, 2012 
Jan-Dec 
2009 
University of 
Benin 
Teaching 
Hospital, 
Nigeria 
Retrospective 
Cohort Study 
298 HIV 
Exposed 
Infants 
ART 
 
Overall 2.1% 
13.6±12.7 
wks 
          
***Okafor 
et al., 2014 
Jan 
2009 – 
Dec 
2011 
Enugu State 
University 
Teaching 
Hospital, 
Nigeria 
Cohort Study 
5,946 
ANC 
Attendee
s 
184 HIV 
Exposed 
Infants 
ART 
AZT + ETC +NVP 
or EFV OR 
TDF+3TC +EFV 
NVP or 
AZT for 6 
wks 
Overall 
+++
0.0% 
6 wks  and 
18 months 
          
Inalegwu et 
al., 2016 
Jan 
2008-
Dec 
2012 
150 health 
facilities 
Analysis of 
EID data 
32,552 
DBS test 
samples 
Number 
of 
samples 
tested 
(Accepte
d 
samples 
tested) = 
31,766  
Number 
of 
rejected 
samples 
  
Accepted 
Samples  
Tested 
9.8% 
17.83 wks 
Standard 
Deviation 
(SD)= 
15.29; 
95%CI: 
17.65-
18.01) 
 
Rejected 
Samples 
Tested 
15.9% 
20.30 wks 
(SD = 
14.31; 
95%CI: 
16.53-
24.06) 
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Authors 
name 
Study 
Period 
Study Site Methodology 
Sample 
Size 
PMTCT/ART Regimen 
MTCT Risk 
Age of 
Testing Mother Infant 
re-tested 
(Repeat 
samples 
tested) = 
69 
          
Isah et al, 
2016 
2008 -
2012 
University of 
Nigeria 
Teaching 
Hospital 
Retrospective 
review 
373 HIV 
positive 
pregnant 
women 
367 HIV 
Exposed 
Infants 
AZT/3TC/NVP, 
TDF/3TC+NVP 
and 
AZT/3TC+EFV 
NVP and 
AZT 
Overall 2.2% 6 weeks 
          
Aliyu et al., 
2014 
2009-
2012 
Four 
secondary 
level 
facilities, 
namely: Sobi 
Specialist 
Hospital and 
Lafiagi 
General 
Hospital in 
Kwara state 
as well as  
Gawu 
Babangida 
Rural 
Hospital and  
Observational 
study: 
retrospective 
review of 
routine data 
712 
HIV-
infected 
pregnant 
women 
357 HIV 
Exposed 
Infants 
Option A or triple 
regimen ART 
AZT+3TC+NVP or 
2 new NRTIs + 
LPV/r 
NVP for 6 
wks 
Overall ****11.0% 
17 wks (9-
34 wks) 
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Authors 
name 
Study 
Period 
Study Site Methodology 
Sample 
Size 
PMTCT/ART Regimen 
MTCT Risk 
Age of 
Testing Mother Infant 
Umaru Yar 
Adua 
Memorial 
Hospital in 
Niger State 
        
 
 
*****Marks
on & Umoh, 
2012 
 
Jan - 
Dec 
2010 
General 
Hospital 
Oron, Akwa 
Ibom state, 
Nigeria 
Cross 
Sectional 
Descriptive 
2,632 
First 
ANC 
Attendee
s 
398 HIV 
positive 
pregnant 
women 
398 HIV 
Exposed 
Infants 
  
Overall 4.0% 18 months 
          
Sagay et al., 
2015 
2010-
2012 
Jos 
University 
Teaching 
Hospital, 
Nigeria 
Retrospective 
Observational 
Study 
996 HIV 
Exposed 
Infants 
Option B 
 
Overall 0.7% 
18 months 
mART or 
MP (triple 
regimen) 
before 
pregnancy 
0.4% 
P=0.0
5 mART 
(triple 
regimen) 
during 
pregnancy 
2.0% 
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Authors 
name 
Study 
Period 
Study Site Methodology 
Sample 
Size 
PMTCT/ART Regimen 
MTCT Risk 
Age of 
Testing Mother Infant 
or delivery 
           
Ikechebelu 
et al., 2011 
1 year 
Nnamdi 
Azikiwe 
University 
Teaching 
Hospital, 
Nnewi 
Southeast 
Nigeria 
Prospective 
Descriptive 
Study 
726 
mother-
infant 
pairs 
  
mART+ IP 
+ RF 
2.8% 
p<0.0
1 
 
mART+ IP 
+IB 
12.5% 
No 
interventio
n + RF 
21.1% 
p<0.0
2 No 
interventio
n + IB 
37.5% 
Kalu et al., 
2014 
Jan 
2012 - 
Feb 
2013 
Prospective 
Cohort Study 
583 
mother-
infant 
pair 
ART or Option B 
PMTCT  
Overall 3.3% ( 2.0, 5.0) 
6 weeks - 
>6 months 
MP or 
mART 
+IP+RF 
0.8% 
MP or 
mART 
+IP+EBF 
1.7% 
MP or 
mART 
+IP+MF 
5.9% 
No 
interventio
n + RF 
5.1% 
No 
interventio
n +EBF 
6.7% 
No 
interventio
23.5% 
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Authors 
name 
Study 
Period 
Study Site Methodology 
Sample 
Size 
PMTCT/ART Regimen 
MTCT Risk 
Age of 
Testing Mother Infant 
n + MF 
          
Chukwueme
ka et al., 
2014 
Jan 
2011 - 
Dec 
2012 
National 
Hospital 
Abuja, 
Nigeria 
Retrospective 
review of 
EID records 
of exposed 
infants 
515 HIV 
Exposed 
Infants 
 
sd NVP at 
birth AZT 
for 6 
weeks 
MP or 
mART + 
IP 
1.30% 
Mean age 
of  4 
months 
MP or 
mART 
only 
4.60% 
IP only 20.0% 
No 
interventio
n 
66.7% 
          
Ben & 
Yusuf, 2014 
Jan 
2011 - 
Dec 
2012 
Usman 
Danfodio 
University 
Teaching 
Hospital, 
Sokoto, 
Nigeria 
Cross 
Sectional 
Study 
163 HIV 
Exposed 
Infants 
ART 
AZT+3TC+NVP or 
EFV 
sdNVP 
within 72 
hours of 
birth and 
continued 
for 6 wks 
Overall 1.8% 
6-8 weeks 
ART 
Before 
Pregnancy 
0.0% 
ART 
During 
Pregnancy 
1.6% 
No 
interventio
n 
16.7% 
EBF 0.7% 
MF 8.7% 
+
Irrespective of viral load;
 ++
only one infant in the study was mixed fed, 
+++Mothers had ≥4 months of ART 2 infants died in utero and hence 
their HIV status could not be determined while 4 infants that tested HIV negative at 6 weeks also died the age of 18 months; *Maternal HIV 
positivity rate (MHP) =12.3%; **MHP=12.7%; *** MHP=3.7%; ****67 Results were missing,*****MHP= 15.1%, HIV Counselling and 
Testing Uptake = 99.2%; Overall represents MTCT risk in the entire study group irrespective of intervention; 3TC, Lamivudine; ART, 
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Antiretroviral Therapy; AZT, Zidovudine; BF, Breastfeeding; CI, Confidence Interval; d4T, Stavudine; EBF, Exclusive Breast Feeding; ECSD, 
Elective Caesarian Section Delivery; FTC, Emtricitabine;  HF, Health Facility; IB, Infant Breastfed; IDV/r, Indinavir/ritonavir; IP, Infant ARV 
Prophylaxis; LPV/r, Lopinavir/ritonavir; mART, maternal Antiretroviral Therapy; MF, Mixed Feeding; MP, Maternal ARV Prophylaxis; NVP, 
Nevirapine; sdNVP, single dose, Nevirapine; RF, Replacement Feeding; TDF, Tenofovir; wks, Weeks  
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Appendix 6: Information to be extracted for HIV positive pregnant women and HEIs 
Tool Data Elements Source Location 
Data 
Collection 
Tool 1 
Aggregate count of 
pregnant women that 
attended ANC for the 
first time in the most 
recent pregnancy by 
month 
ANC Register ANC Clinic 
Aggregate count of 
pregnant women that 
tested for HIV during 
the first ANC visit by 
month 
PMTCT/HTC register ANC Clinic 
 
 
 
 
 
 
 
 
 
Data 
Collection 
Tool 2: 
 
HIV positive 
pregnant mother’s 
age, gestation age, 
gravida, parity, 
marital status, 
educational level and 
occupational status 
ANC register 
For marital status, educational 
level and occupational status 
check adult initial clinical 
evaluation form present in the 
patient’s folder 
 
ANC clinic/ 
Patient 
Monitoring and 
Management 
Unit 
Acceptance/non-
acceptance of 
prophylaxis/ART 
and the type of ARV 
used 
PMTCT/HTC register ANC clinic 
(if unavailable, use hospital 
number as a guide and check 
Pharmacy daily worksheet 
Pharmacy 
Department 
OR patient folder) 
Patient 
Monitoring and 
Management 
Unit 
Data 
Collection 
Tool 3: 
Age of the infant, 
receipt or non-receipt 
of maternal/infant 
prophylaxis and the 
ARV used, infant 
feeding option, 
outcome of HIV test 
EID register/infant follow up 
register HIV PCR request and 
result forms 
Pediatric Unit 
http://etd.uwc.ac.za
101 
 
 
Appendix 7: Data collection tool 1 for data abstraction 
Data elements 
Jan-
08 
Feb-
08 
Mar-
08 
Apr-
08 
May-
08 
Jun-
08 
Jul-
08 
Aug-
08 
Sep-
08 
… 
Dec-
14 
Aggregate count of pregnant women that attended ANC 
for the first time in the most recent pregnancy by month                       
Aggregate count of pregnant women that tested for HIV 
during the first ANC visit by month            
Aggregate count of first ANC attendees that accepted 
HIV testing that tested HIV positive by month                       
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Appendix 8: Data collection tool 2 for data abstraction 
   
Unique Identification number 
S/N Data Elements 1 2 3 4 5 6 7 8 9 10 
1 
Age in years (insert 99 for missing 
record)                     
2 
Gestation Age in weeks (insert 99 for 
missing record)                     
3 Gravida (insert 99 for missing record)                     
4 Parity (insert 99 for missing record)                     
5 Marital Status 
Single (1)                     
Married (2)                     
Widowed (3)                     
Separated (4)                     
Divorced (5)           
Missing (6)                     
6 Educational Level 
None (1)                     
Primary (2)                     
Senior 
Secondary (3)                     
Qur'anic (4)                     
Junior 
Secondary (5)                     
Post-
Secondary (6)           
Missing (7)                     
7 
Occupational 
Status 
Unemployed 
(1)                     
Employed (2)                     
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Unique Identification number 
S/N Data Elements 1 2 3 4 5 6 7 8 9 10 
Student (3)                     
Retired (4)           
Missing (5)                     
8 Received ARV 
Yes (1)                     
No (2)           
Missing (3)                     
9 
Type of ARV 
received   
ART (1)                     
Triple 
(ARVP) (2)                     
AZT/3TC (3)                     
AZT (4)                     
Sd NVP (5)           
Missing (6)                     
 
 Data Elements 1-4 to be extracted from General ANC Register 
 Data Elements 5-7 to be extracted from adult initial clinical evaluation form present in the patient folder 
 Data element 8 and 9 to be extracted from PMTCT/HTC register if available, if not, it will be extracted from Pharmacy daily worksheet 
or Patient’s folder 
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Appendix 9: Data collection tool 3 for data abstraction 
Data Elements 
Unique identification number 
1 2 3 4 5 6 7 8 9 10 
Month/Year of Sample Collection           
Age in weeks (insert 99 for missing record) 
          
Reason for PCR 
1st test for HEI (1) 
          
1st test for sick 
infant (2)           
Repeat  6 weeks 
post cessation of 
breastfeeding (3) 
          
Prob with 1st test 
(4)           
Confirmation of 
1st test (5) 
          
Missing (6) 
          
Result of rapid 
test for ≥ 9 
months 
Negative (1) 
          
Positive (2) 
          
Indeterminate (3)           
Missing (4) 
          
ART During 
pregnancy 
Yes (1) 
          
No (2)           
Missing (3) 
          
Time of During (1) 
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Data Elements 
Unique identification number 
1 2 3 4 5 6 7 8 9 10 
commencement if 
yes 
After (2)           
Missing (3) 
          
Received ARV 
prophylaxis 
Yes (1) 
          
No (2)           
Missing (3) 
          
If Yes Type of 
ARV received 
AZT+3TC+sdNVP 
in labour (1)           
AZT+sdNVP in 
labour (2)           
sdNVP in labour 
(3)           
Triple Regimen 
ARVP (4)           
Unknown (5)           
Missing (6) 
          
Intervention 
received by infant 
Yes (1) 
          
No (2)           
Missing (3) 
          
If Yes Type of 
ARV 
AZT+sdNVP (1) 
          
NVP (2) 
          
Unknown (3)           
Missing (4) 
          
Infant ever 
breastfed 
Yes (1) 
          
No (2) 
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Data Elements 
Unique identification number 
1 2 3 4 5 6 7 8 9 10 
Unknown (3)           
Missing (4) 
          
Breastfeeding 
now 
Yes (1) 
          
No (2) 
          
Unknown (3)           
Missing (4) 
          
Breastfeeding 
option 
Exclusively breast 
fed (1) 
          
Mixed fed (2)           
Not breastfed (3)           
Missing (4)           
Age at breastfeeding cessation in 
months (insert 99 for missing record)           
CTX given to 
infant 
No (1) 
          
Yes takes daily (2) 
          
Yes starts today 
(3) 
          
Missing (4) 
          
PCR Test Result 
Positive (1)           
Negative (2)           
Missing (3)           
Date Specimen Collected dd/mm/yy 
(insert 00/00/00 for missing record) 
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Data Elements 
Unique identification number 
1 2 3 4 5 6 7 8 9 10 
Date test result received at facility 
dd/mm/yy (insert 00/00/00 for missing 
record) 
          
Age in months (2
nd
 PCR Test) (insert 99 
for missing record) 
          
Result of rapid 
test (2nd PCR 
Test) 
Positive (1)           
Negative (2)           
Missing (3)           
PCR Test Result 
(2nd PCR Test) 
Positive (1)           
Negative (2)           
Missing (3)           
Date Specimen Collected dd/mm/yy 
(2nd PCR Test) (insert 00/00/00 for missing 
record) 
          
Date test result received at facility 
dd/mm/yy  (2nd PCR Test) (insert 
00/00/00 for missing record) 
          
   
 Information contained in the data collection tool is to be extracted from EID/Infant follow up register/PCR Request and Result form
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Appendix 10: Data analysis plan 
Uptake of HTC, Antenatal HIV prevalence 
Total number of first ANC 
attendees 
A 
  
Total number that accepted HTC B B/A % Uptake of HTC 
Total number that tested HIV 
positive 
C C/B % Antenatal HIV prevalence 
Baseline Characteristics of HIV Positive Pregnant women by Hospital 
Age 
15-24 (n)% 
25-34 (n)% 
35-44 (n)% 
45 and above (n)% 
Missing (n)% 
Gestation Age 
<14 weeks (n)% 
14 -27 weeks (2nd Trimester) (n)% 
28 weeks and above (3rd Trimester) (n)% 
Missing (n)% 
Gravida 
0-4 (n)% 
>4 (n)% 
Missing (n)% 
Parity 
0-4 (n)% 
>4 (n)% 
Missing (n)% 
Marital Status 
Single (n)% 
Married (n)% 
Widowed (n)% 
Separated (n)% 
Divorced (n)% 
Missing (n)% 
Educational Level 
None (n)% 
Primary (n)% 
Junior Secondary (n)% 
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Senior Secondary (n)% 
Post-Secondary (n)% 
Qur'anic (n)% 
Post-Secondary (n)% 
Missing (n)% 
Occupational Status 
Unemployed (n)% 
Employed (n)% 
Student (n)% 
Missing (n)% 
n=number 
Uptake of ART/ARV prophylaxis among HIV positive pregnant women 
Total number of HIV positive 
pregnant women that received 
ARV prophylaxis or ART 
D 
D/C 
% 
Uptake of 
ART/ARV 
prophylaxis 
Types of ARVs used by HIV positive pregnant women that received ART or ARVP 
sdNVP (n)% 
AZT (n)% 
AZT/3TC (n)% 
AZT+3TC+sdNVP (n)% 
Triple Regimen (ARVP) (n)% 
ART (n)% 
Missing (n)% 
A, B, C, D are variables 
Association between Age, Parity, Gestation Age, Marital status, Educational level and 
Occupational status and ART/ARV prophylaxis uptake 
Age *15-24 
Estimate Odds 
Ratio (OR), 
Adjusted OR with 
associated p-values 
 
25-34 
 
35-44 
 
45 and above 
Gestation Age *<14 weeks 
 
14 -27 weeks 
 
28 weeks and above 
Gravida *0-4 
 
>4 
Marital Status 
 
 
*Single, Widowed, Separated, 
Divorced 
 
Married 
Educational Level 
 
 
*None 
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Primary 
 
Qur'anic 
 
Secondary 
 
Post-Secondary 
Occupational Status 
 
 
*Unemployed 
 
Employed 
 
Student 
Hospital 
 
*FMC Yola 
 
SH Yola 
Year 
 
*2008 
 
2009 
 
2010 
 
2011 
 
2012 
 
2013 
 
2014 
*reference 
Baseline characteristics and prophylaxis status for HIV exposed infants/HIV outcome in 
HEI and average turnaround time 
Gender 
Male (n) % 
Female (n) % 
Age 
≤6 weeks (n) % 
>6 weeks to 2 months (n) % 
>2months – 6 months (n) % 
>6 - 12 months (n) % 
>12 months (n) % 
Missing (n) % 
Infant Feeding Option 
Exclusive breastfeeding (n)% 
Not Breastfed or Replacement 
feeding 
(n)% 
Mixed feeding (n)% 
Missing (n)% 
Reason for PCR 
First test for healthy HEIs (n)% 
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First test for sick infant (n)% 
Problem with first test (n)% 
Maternal ARVs 
ART (n)% 
ARVP (n)% 
ART or Triple Regimen (n)% 
None (n)% 
Missing (n)% 
Type of Maternal ARVP 
AZT + 3TC and sdNVP (n)% 
AZT and sdNVP in labour (n)% 
Triple Regimen (n)% 
sdNVP (n)% 
Unknown (n)% 
Missing (n)% 
Infant ARVs 
sdNVP at birth (n)% 
sdNVP at birth and AZT for 4 weeks (n)% 
NVP for 6 weeks (n)% 
Unknown (n)% 
None (n)% 
Missing (ARV Type) (n)% 
Missing (Prophylaxis use) (n)% 
HIV outcome 
Positive (n)% 
Negative (n)% 
Overall MTCT risk (n)% 
Median Turnaround Time with 
IQR 
x days 
x=variable 
MTCT risk by receipt of ART/ARV and breastfeeding option (Estimate 95% CI) 
 
n (MTCT risk) 
95% CI 95% CI 
Lower band Upper band 
Age 
≤6 weeks 
   
>6 weeks to 2 months 
   
>2months – 6 months 
   
>6 - 12 months 
   
>12 months 
   
Missing 
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Infant feeding Option 
Exclusive breastfeeding 
   
Mixed feeding 
   
Not Breastfed or Replacement 
feeding    
Missing 
   
Receipt of ART/ARV 
Both Mother and Infant 
   
Mother alone 
   
Infant alone 
   
Neither mother or infant 
   
PMTCT Protocol Period 
January 2008 – January  2010 
(Period 1)    
February 2010 – May 2012-
Transitional period    
June 2012-December 2014 – Period 
2    
Simple and Multiple Logistics Regression Analysis 
Gender 
 
Estimate Odds Ratio (OR), 
Adjusted OR with associated 
p-values 
 
*Male 
 
Female 
Age 
 
 
*≤6 weeks 
 
>6 weeks to 2 months 
 
>2months – 6 months 
 
>6 - 12 months 
 
>12 months 
Infant feeding Option 
 
 
*Not 
Breastfed/Replacement 
Feeding 
 
Exclusively Breastfed 
 
Mixed fed 
Receipt of ART/ARV 
 
 
*Both Mother and 
Infant 
 
Mother alone 
 
Infant alone 
 
Neither mother or 
infant 
Hospital 
 
http://etd.uwc.ac.za
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*FMC Yola 
 
SH Yola 
Year *2008 
 
2009 
 
2010 
 
2011 
 
2012 
 
2013 
 
2014 
*reference 
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Appendix 11 Ethics approval from the University of the Western Cape 
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Appendix 12: Ethics approval for Federal Medical Centre Yola 
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Appendix 13: Ethics approval for Specialist Hospital Yola 
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Appendix 14: Ethics approval from Adamawa State Ministry of Health 
 
